Patent Grant
11937987
An artificial pacemaker is a medical device that helps control abnormal heart rhythms. A pacemaker uses electrical pulses to prompt the heart to beat at a normal rate. The pacemaker may speed up a slow heart rhythm, control a fast heart rhythm, and coordinate the chambers of the heart. The implantable portions of a pacemaker system generally comprise three main components: a pulse generator, one or more wires called leads, and electrodes found on each lead. The pulse generator produces the electrical signals that make the heart beat. Most pulse generators also have the capability to receive and respond to signals that are sent by the heart. Leads are insulated flexible wires that conduct electrical signals to the heart from the pulse generator. The leads may also relay signals from the heart to the pulse generator. One end of the lead is attached to the pulse generator and the electrode end of the lead is positioned on or in the heart.
Methods and apparatuses for use in medical procedures are disclosed. Some implementations may include a medical procedure guide that can overlay portions of anatomy of a patient, where the guide may include alignment markings to facilitate proper placement, procedure markings to facilitate determination of a position at which to commence a medical procedure, and/or imaging markers incorporated within the guide to facilitate commencement or completion of the medical procedure in conjunction with imaging.
In some variations, the guide may include critical anatomy markings, or may be flexible to at least partially form to the anatomy of a patient. The guide may be affixed to the patient, for example, with an adhesive, and may be designed to allow for puncture or incision through the guide during a medical procedure.
In other implementations, imaging markers may facilitate determination of the position to commence a medical procedure, to facilitate determination of the presence or absence of interposed lung, or to facilitate the determination of a distance between a sternal margin and a thoracic vain or thoracic artery.
In some implementations imaging markers may be located at particular known depths within the guide to facilitate completion of the medical procedure. The imaging markers may be radiopaque.
In one implementation, the medical procedure may involve insertion of a cardiac therapy lead for pacing or defibrillation and the guide's alignment markings may be configured to line up with at least a portion of the patient's sternum and at least one rib. The procedure markings may also be configured to locate a position proximate a lateral margin of the patient's sternum, in the region of a cardiac notch. The imaging markers may also facilitate determination of a proper depth of insertion for the cardiac therapy lead. In some implementations, the guide may also facilitate a determination of the distance between a posterior surface of a sternum and a pericardium and/or facilitate a determination of the patient's sternum thickness.
The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will be apparent from the description and drawings, and from the claims. While certain features of the currently disclosed subject matter are described for illustrative purposes in relation to particular implementations, it should be readily understood that such features are not intended to be limiting. The claims that follow this disclosure are intended to define the scope of the protected subject matter.
The accompanying drawings, which are incorporated in and constitute a part of this specification, show certain aspects of the subject matter disclosed herein and, together with the description, help explain some of the principles associated with the disclosed implementations. In the drawings,
When practical, similar reference numbers denote similar structures, features, or elements.
Implantable medical devices (IMDs), such as cardiac pacemakers or implantable cardioverter defibrillators (ICDs), provide therapeutic electrical stimulation to the heart of a patient. This electrical stimulation may be delivered via electrodes on one or more implantable endocardial or epicardial leads that are positioned in or on the heart. This electrical stimulation may also be delivered using a leadless cardiac pacemaker disposed within a chamber of the heart. Therapeutic electrical stimulation may be delivered to the heart in the form of electrical pulses or shocks for pacing, cardioversion or defibrillation.
An implantable cardiac pacemaker may be configured to facilitate the treatment of cardiac arrhythmias. The devices, systems and methods of the present disclosure may be used to treat cardiac arrhythmias including, but not limited to, bradycardia, tachycardia, atrial flutter and atrial fibrillation. Resynchronization pacing therapy may also be provided. While embodiments of the present disclosure refer to a cardiac pacing system, is understood that the implantable medical device may additionally be an implantable defibrillator used to treat disruptive cardiac arrhythmias.
A cardiac pacemaker consistent with the present disclosure may include a pulse generator implanted adjacent the rib cage of the patient, for example, on the ribcage under the pectoral muscles, laterally on the ribcage, within the mediastinum, subcutaneously on the sternum of the ribcage, and the like. One or more leads may be connected to the pulse generator. A lead may be inserted, for example, between two ribs of a patient so that the distal end of the lead is positioned within the mediastinum of the patient adjacent, but not touching, the heart. The distal end of the lead may include an electrode for providing electrical pulse therapy to the patient's heart and may also include at least one sensor for detecting a state of the patient's organs and/or systems. The cardiac pacemaker may include a unitary design where the components of the pulse generator and lead are incorporated within a single form factor. For example, where a first portion of the unitary device resides within the subcutaneous tissue and a second portion of the unitary device is placed through an intercostal space into a location within the mediastinum.
Housing 104 can be substantially rectangular in shape and the first end of the housing 104 may include a tapered portion 108. The tapered portion can include a first tapered edge 110, tapered inwardly toward the transverse plane. The tapered portion 108 can include a second tapered edge 112 tapered inwardly toward the longitudinal plane. Each of the first tapered edge 110 and the second tapered edge 112 may have a similar tapered edge generally symmetrically disposed on the opposite side of tapered portion 108, to form two pairs of tapered edges. The pairs of tapered edges may thereby form a chisel-shape at the first end 106 of pulse generator 102. When used in the present disclosure, the term “chisel-shape” refers to any configuration of a portion of housing 104 that facilitates the separation of tissue planes during placement of pulse generator 102 into a patient. The “chisel-shape” can facilitate creation of a tightly fitting and properly sized pocket in the patient's tissue in which the pulse generator may be secured. For example, a chisel-shape portion of housing 104 may have a single tapered edge, a pair of tapered edges, 2 pairs of tapered edges, and the like. Generally, the tapering of the edges forms the shape of a chisel or the shape of the head of a flat head screwdriver. In some variations, the second end 114 of the pulse generator can be tapered. In other variations, one or more additional sides of the pulse generator 102 can be tapered.
Housing 104 of pulse generator 102 can include a second end 114. The second end 114 can include a port assembly 116. Port assembly 116 can be integrated with housing 104 to form a hermetically sealed structure. Port assembly 116 may be configured to facilitate the egress of conductors from housing 104 of pulse generator 102 while maintaining a seal. For example, port assembly 116 may be configured to facilitate the egress of a first conductor 118 and a second conductor 120 from housing 104. The first conductor 118 and the second conductor 120 may combine within port assembly 116 to form a twin-lead cable 122. In some variations, the twin-lead cable 122 can be a coaxial cable. The twin-lead cable 122 may include a connection port 124 remote from housing 104. Connection port 124 can be configured to receive at least one lead, for example, a pacing lead. Connection port 124 of the cable 122 can include a sealed housing 126. Sealed housing 126 can be configured to envelope a portion of the received lead(s) and form a sealed connection with the received lead(s).
Port assembly 116 may be made from a different material than housing 104. For example, housing 104 may be made from a metal alloy and port assembly 116 may be made from a more flexible polymer. While port assembly 116 may be manufactured separately from housing 104 and then integrated with it, port assembly 116 may also be designed to be part of housing 104 itself. The port assembly 116 may be externalized from the housing 104 as depicted in
Pulse generator 102 can include one or more components. The one or more components may be hermetically sealed within the housing 104 of pulse generator 102. Pulse generator 102 can include a controller 302, configured to control the operation of the pulse generator 102. The pulse generator 102 can include an atrial pulse generator 304 and may also include a ventricular pulse generator 306. Controller 302 can be configured to cause the atrial pulse generator 304 and the ventricular pulse generator 306 to generate electrical pulses in accordance with one or more protocols that may be loaded onto controller 302. Controller 302 can be configured to control pulse generators 304, 306, to deliver electrical pulses with the amplitudes, pulse widths, frequency, or electrode polarities specified by the therapy protocols, to one or more atria or ventricles.
Controller electronic storage 308 can store instructions configured to be implemented by the controller to control the functions of pulse generator 102.
Controller 302 can include a processor(s). The processor(s) can include any one or more of a microprocessor, a controller, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field-programmable gate array (FPGA), or equivalent discrete or analog logic circuitry. The functions attributed to controller 302 herein may be embodied as software, firmware, hardware or any combination thereof.
The pulse generator 102 can include a battery 310 to power the components of the pulse generator 102. In some variations, battery 310 can be configured to charge a capacitor. Atrial pulse generator 304 and ventricular pulse generator 306 can include a capacitor charged by the battery 310. The electrical energy stored in the capacitor(s) can be discharged as controlled by controller 302. The electrical energy can be transmitted to its destination through one or more electrode leads 312, 314. The leads can include a ventricular pulsing lead 312, an atrial pulsing lead 314, and/or other leads.
Pulse generator 102 can include one or more sensors 322. Sensor(s) 322 can be configured to monitor various aspects of a patient's physiology. Sensor(s) 322 may be embedded in the housing of pulse generator 102, incorporated into leads 312, 314 or be incorporated into separate leads. Sensors 322 of pulse generator 102 can be configured to detect, for example, signals from a patient's heart. The signals can be decoded by controller 302 of the pulse generator to determine a state of the patient. In response to detecting a cardiac arrhythmia, controller 302 can be configured to cause appropriate electrical stimulation to be transmitted through electrodes 312 and 314 by atrial pulse generator 304 and/or ventricular pulse generator 306.
Sensor(s) 322 can be further configured to detect other physiological states of the patient, for example, a respiration rate, blood oximetry, and/or other physiological states. In variations where the pulse generator 102 utilizes a plurality of electrodes, controller 302 may be configured to alter the sensing and delivery vectors between available electrodes to enhance the sensitivity and specificity of arrhythmia detection and improve efficacy of the therapy delivered by the electrical impulses from the pulse generator 102.
Pulse generator 102 can include a transceiver 316. The transceiver can include an antenna 318. The transceiver 316 can be configured to transmit and/or receive radio frequency signals. The transceiver 316 can be configured to transmit and/or receive wireless signals having any wireless communication protocol. Wireless communication protocols can include Bluetooth, Bluetooth low energy, Near-Field Communication, WiFi, and/or other radio frequency protocols. The transceiver 316 can be configured to transmit and/or receive radio frequency signals to and/or from a programmer 320. The programmer 320 can be a computing device external to the patient. Programmer 320 may comprise a transceiver configured to transmit and/or receive radio frequency signals to and/or from the transceiver 316 of the pulse generator 102. Transceiver 316 can be configured to wirelessly communicate with programmer 320 through induction, radio-frequency communication or other short-range communication methodologies.
In some variations, programmer 320 can be configured to communicate with the pulse generator 102 through longer-range remote connectivity systems. Such longer-range remote connectivity systems can facilitate remote access, by an operator, to pulse generator 102 without the operator being in close proximity with the patient. Longer-range remote connectivity systems can include, for example, remote connectivity through the Internet, and the like. When an operator connects with pulse generator 102 through longer-range remote connectivity systems, a local device can be positioned within a threshold distance of the patient. The local device can communicate using one or more radio-frequency wireless connections with the pulse generator 102. The local device can, in turn, include hardware and/or software features configured to facilitate communication between it and an operator device at which the operator is stationed. The local device can be, for example, a mobile computing device such as a smartphone, tablet, laptop, and the like. The local device can be a purpose-built local device configured to communicate with the pulse generator 102. The local device can be paired with the pulse generator 102 such that the communications between the pulse generator 102 and the local device are encrypted. Communications between the local device and the operator device can be encrypted.
Programmer 320 can be configured to program one or more parameters of the pulse generator 102. The parameter(s) can include timing of the stimulation pulses of the atrial pulse generator, timing of the stimulation pulses of the ventricular pulse generator, timing of pulses relative to certain sensed activity of the anatomy of the patient, the energy levels of the stimulation pulses, the duration of the stimulation pulses, the pattern of the stimulation pulses and other parameters. The programmer 320 can facilitate the performance of diagnostics on the patient or the pulse generator 102.
Programmer 320 can be configured to facilitate an operator of the programmer 320 to define how the pulse generator 102 senses electrical signals, for example ECGs, and the like. The programmer 320 can facilitate an operator of the programmer 320 to define how the pulse generator 102 detects cardiac conditions, for example ventricular dyssynchrony, arrhythmias, and the like. The programmer 320 can facilitate defining how the pulse generator 102 delivers therapy, and communicates with other devices.
An operator can fine-tune parameters through the programmer 320. For example, the sensitivity of sensors embodied in the housing of the pulse generator 302, or within leads, can be modified. Programmer 320 can facilitate setting up communication protocols between the pulse generator 102 and another device such as a mobile computing device. Programmer 320 can be configured to facilitate modification of the communication protocols of the pulse generator 102, such as adding security layers, or preventing two-way communication. Programmer 320 can be configured to facilitate determination of which combination of implanted electrodes are best suited for sensing and therapy delivery.
Programmer 320 can be used during the implant procedure. For example, programmer 320 can be used to determine if an implanted lead is positioned such that acceptable performance will be possible. If the performance of the system is deemed unacceptable by programmer 320, the lead may be repositioned by the physician, or an automated delivery system, until the lead resides in a suitable position. Programmer 320 can also be used to communicate feedback from sensors disposed on the leads and housing 104 during the implant procedure.
In some cases, concomitant devices such as another pacemaker, an ICD, or a cutaneous or implantable cardiac monitor, can be present in a patient, along with pulse generator 102. Pulse generator 102 can be configured to communicate with such concomitant devices through transceiver 316 wirelessly, or the concomitant device may be physically connected to pulse generator 102. Physical connection between devices may be accomplished using a lead emanating from pulse generator 102 that is compatible with the concomitant device. For example, the distal end of a lead emanating from pulse generator 102 may be physically and electrically connected to a port contained on the concomitant device. Physical connection between devices may also be accomplished using an implantable adaptor that facilitates electrical connection between the lead emanating from pulse generator 102 and the concomitant device. For example, an adapter may be used that will physically and electrically couple the devices despite not having native components to facilitate such connection. Concomitant devices may be connected using a “smart adapter” that provides electrical connection between concomitant devices and contains signal processing capabilities to convert signal attributes from each respective device such that the concomitant devices are functionally compatible with each other.
Pulse generator 102 can be configured to have a two-way conversation or a one-way conversation with a concomitant device. Controller 302 can be configured to cause the concomitant device to act in concert with pulse generator 102 when providing therapy to the patient, or controller 302 can gather information about the patient from the concomitant device. In some variations, pulse generator 102 can be configured to be triggered via one-way communication from a concomitant device to pulse generator 102.
In other variations, pulse generator 102 can be disposed outside of a patient's ribcage in a pectoral position, outside of the patient's ribcage in a lateral position, below (inferior to) the patient's ribcage in a subxiphoid or abdominal position, within the patient's mediastinum, or the like.
Lead 414 may be passed through the ribcage so the distal end of the lead and its electrodes are disposed on, or pass through, the inner surface of the rib or inner surface of the innermost intercostal muscle, or may alternatively traverse further within the thoracic cavity, but without physically contacting the tissue comprising the heart. This placement may be referred to herein as intracostal or intracostally.
Leads may be inserted between any two ribs within the thoracic cavity, for example, as shown in
Precise placement of a distal end of lead 414, which may include electrode(s) for defibrillation, pacing or sensing, is now described further with reference to the anatomical illustrations of
The distal end of lead 414 can also be positioned so as to abut the parietal pleura of the lung 426. In other variations, the distal end of lead 414 can be positioned so as to terminate within the mediastinum 428 of the thoracic cavity of the patient, proximate the heart 418, but not physically in contact with the heart 418 or the pericardium 432 of heart 418. Alternatively, the distal end of lead 414 can be placed to abut the pericardium 432, but not physically attach to the epicardial tissue comprising the heart.
A portion of lead 414 may be configured to include a preformed particular shape (e.g., including a 45 degree angle bend, a 90 degree angle bend, a coil, or the like) that enables the preformed portion of lead 414 to be directed towards a preferred location as it is inserted into the patient. For example, the distal end of lead 414 may be preformed so it creates an angle of 90 degrees relative to the main body of lead 414. While lead 414 is being implanted, a sheath or delivery tool may be used to constrain the preformed portion of lead 414 into a straight shape. However, as lead 414 is deployed from the sheath or delivery tool, the preformed portion of lead 414 can revert to its preformed shape. In one instance, the preformed portion of lead 414 reverts to a shape that enables the distal end of lead 414 to reside along and against the posterior surface of the anterior chest wall. Alternatively, a stylet may be used to straighten the preformed shape during the insertion process. Upon removal of the stylet, the preformed shape is again assumed. Any number of preformed shapes are contemplated to facilitate the placement of lead(s) in the positions and particular orientations disclosed herein.
The distal end of lead 414 may be physically affixed to cartilage or bone found within the thoracic cavity, for example, to a rib, to cartilage of a rib, or to other bone or cartilage structure in the thoracic cavity. In one variation, the lead can be disposed such that it is wrapped around the patient's sternum 402 or a patient's rib.
For certain placements, lead 414 can be adequately fixed by direct physical contact with surrounding tissue. In other variations, an additional fixation mechanism may be used at various points along the body of the lead 414. For example, the distal end of lead 414 can incorporate a fixation mechanism such as a tine, hook, spring, screw, or other fixation device. The fixation mechanism can be configured to secure the lead in the surrounding tissue, cartilage, bone, or other tissue, to prevent the lead from migrating from its original implantation location or orientation.
Delivery system 602 includes a proximal end 606 and a distal end 608. The distal end 608 of delivery system 602 contains a receptacle 610 in which the housing of the pulse generator 102 is loaded. Where the pulse generator 102 contains a connection lead, the delivery system 602 can be configured to accommodate the connection lead so that the connection lead will not be damaged during the implantation of the pulse generator 102.
When pulse generator 102 is fully loaded into delivery system 602, pulse generator 102 is substantially embedded into the receptacle 610. In some variations, a portion of the pulse generator 102's distal end can be exposed, protruding from the end of receptacle 610. The tapered shape of the distal end 106 of pulse generator 102 can be used in conjunction with the delivery system 602 to assist with separating tissue planes as delivery system 602 is used to advance pulse generator 102 to its desired location within the patient.
In some variations, the entirety of pulse generator 102 can be contained within receptacle 610 of the delivery system 602. The pulse generator 102 in such a configuration will not be exposed during the initial advancement of delivery system 602 into the patient. The distal end 608 of delivery system 602 may be designed to itself separate tissue planes within the patient as delivery system 602 is advanced to the desired location within the patient.
The pulse generator delivery system 602 may be made from a polymer, a metal, a composite material or other suitable material. Pulse generator delivery system 602 can include multiple components. Each component of the pulse generator delivery system 602 can be formed from a material suitable to the function of the component. The pulse generator delivery system 602 can be made from a material capable of being sterilized for repeated use with different patients.
Pulse generator delivery system 602 may include a handle 612. Handle 612 can facilitate advancement of delivery system 602 and pulse generator 102 into a patient's body. Handle 612 can be disposed on either side of the main body 614 of the delivery system 602, as illustrated in
Pulse generator delivery system 602 can include a pulse generator release device 618. The release device 618 can be configured to facilitate disengagement of the pulse generator 102 from the delivery system 602. In some variations, release device 618 can include a plunger 620. Plunger 620 can include a distal end configured to engage with the proximal end 606 of the pulse generator delivery system 602. The plunger 620 can engage with the proximal end 606 of the pulse generator delivery system 602 when the pulse generator 102 is loaded into the receptacle 610 of the delivery system 602. The proximal end 622 of the plunger 620 can extend from the proximal end 606 of the delivery system 602.
Plunger 620 can include a force applicator 624. Force applicator 624 can be positioned at the proximal end 622 of plunger 620. Force applicator 624 can be configured to facilitate application of a force to the plunger 620 to advance the plunger 620. Advancing plunger 620 can force pulse generator 102 from the delivery system 602. In some variations, the force applicator 624 can be a ring member. The ring member can facilitate insertion, by the physician, of a finger. Pressure can be applied to the plunger 620 through the ring member, forcing the pulse generator 102 out of the receptacle 610 of the delivery system 602 into the patient at its desired location. In some variations, the proximal end 622 of the plunger 620 can include a flat area, for example, similar to the flat area of a syringe, that allows the physician to apply pressure to the plunger 620. In some variations, the plunger 620 can be activated by a mechanical means such as a ratcheting mechanism.
The distal end 608 of the pulse generator delivery device 602 can include one or more sensors. The sensor(s) can be configured to facilitate detection of a state of patient tissues adjacent distal end 608 of the pulse generator delivery device 602. Various patient tissues can emit, conduct and/or reflect signals. The emitted, conducted and/or reflected signals can provide an indication of the type of tissue encountered by the distal end 608 of the pulse generator delivery device 602. Such sensor(s) can be configured, for example, to detect the electrical impedance of the tissue adjacent the distal end 608 of the pulse generator delivery device 602. Different tissues can have different levels of electrical impedance. Monitoring the electrical impedance can facilitate a determination of the location, or tissue plane, of the distal end 608 of the delivery device 602.
In addition to delivery of the pulse generator, delivery of at least one lead for sensing and/or transmitting therapeutic electrical pulses from the pulse generator is typically required. Proper positioning of the distal end of such lead(s) relative to the heart is very important. Delivery systems are provided that can facilitate the insertion of one or more leads to the correct location(s) in the patient. The delivery systems can facilitate finding the location of the initial insertion point for the lead. The initial insertion point optionally being an intercostal space associated with a patient's cardiac notch of the left lung. The intercostal spaces associated with the cardiac notch commonly include the left-hand-side fourth, fifth and sixth intercostal spaces. Other intercostal spaces on either side of the sternum may be used, especially when the patient is experiencing conditions that prevent use of the fourth, fifth and sixth intercostal spaces, or due to anatomical variations.
When making the initial insertion through the epidermis and the intercostal muscles of the patient, it is important to avoid damaging important blood-filled structures of the patient. Various techniques can be employed to avoid damaging important blood-filled structures. For example, sensors can be used to determine the location of the blood-filled structures. Such sensors may include accelerometers configured to monitor pressure waves caused by blood flowing through the blood-filed structures. Sensors configured to emit and detect light-waves may be used to facilitate locating tissues that absorb certain wavelengths of light and thereby locate different types of tissue. Temperature sensors may be configured to detect differences in temperature between blood-filled structures and surrounding tissue. Lasers and detectors may be employed to scan laser light across the surface of a patient to determine the location of subcutaneous blood-filled structures.
Conventional medical devices may be employed to locate the desired initial insertion point into the patient. For example, x-ray machines, MRI machines, CT scanning machines, fluoroscopes, ultrasound machines and the like, may be used to facilitate determination of the initial insertion point for the leads as well as facilitate in advancing the lead into the patient.
Medical procedure guides can be utilized to bolster the reliability of locating a desired point on a patient for performing a medical procedure. For example, a medical procedure can include, for example, inserting or delivering a lead to a portion of an anatomy of a patient. Medical procedure guides can also identify critical structures to be avoided, for example while inserting the lead during the medical procedure.
For example, the medical procedure guide 1910 may contain markers or regions on the medical procedure guide 1910 meant to be disposed over anatomical locations on the patient. Once the physician has found those anatomical locations (e.g., the xyphoid process), the physician can place the medical procedure guide 1910 so that the markers or desired regions on the medical procedure guide 1910 correlate with those anatomical locations. With the medical procedure guide 1910 properly positioned on the patient, the physician can then use markings on the medical procedure guide 1910 to locate a desired initial insertion point 1940 or to determine the position at which to commence a medical procedure. The medical procedure guide 1910 can be used with many medical procedures including, but not limited to, insertion of a cardiac therapy lead for pacing or defibrillation. In this way, the medical procedure guide 1910 can be configured to allow for puncture or incision through the guide during the medical procedure. Markings, such as critical anatomy markings, on the medical procedure guide 1910 can also indicate structures to be avoided during the lead delivery process. For example, the medical procedure guide 1910 can be configured to further facilitate a determination of the presence or absence of an interposed lung or facilitate a determination of a distance between a sternal margin and a thoracic vein or a thoracic artery.
As used herein, “markings” or “marking regions” refer to marks, recesses, ridges, or other structural features of the medical procedure guide 1910 that are added to the medical procedure guide 1910 (e.g., coloration, changes in opacity, etc.). Markings or marking regions also refer to features that are added to or subtracted from the material that makes up the medical procedure guide 1910. For example, ridges, scoring, recesses, openings and the like.
In some implementations, the medical procedure guide 1910 can have a shape configured to overlay portions of an anatomy of the patient. Portions of the anatomy can include, for example, skin, exposed organs, muscles, tissues, bones, and the like. The shape of the medical procedure guide 1910 can be rectangular, square, circular, oval, or irregular. The medical procedure guide 1910 can be similar to a sheet and have a thickness and an area bounded by a perimeter that overlays the portion of the anatomy. As shown in
The medical procedure guide 1910 can also include alignment markings 1920 on the medical procedure guide 1910 to facilitate proper placement of the medical procedure guide 1910 on the patient. As one example, the alignment markings 1920 can be configured to line up with at least a portion of the patient's sternum and at least one rib.
Procedure markings 1940 can also be included on the medical procedure guide 1910 to facilitate determination of a position at which to commence a medical procedure. For example, the procedure markings 1940 can be configured to locate a position proximate the patient's sternum, in the region of a cardiac notch.
Also, imaging markers may be incorporated with the medical procedure guide 1910 to facilitate commencement or completion of the medical procedure in conjunction with imaging. As used herein, “imaging markers” refer to any markers that are added to or otherwise included with medical procedure guide 1910. A marker can be, in some implementations, an object inserted into or integral with medical procedure guide 1910. In other implementations, the marker can be a feature such as a dye or other material that can be detected by an imaging device or discerned by the human eye. For example, medical procedure guide 1910 can be used with conventional imaging devices such as CT, x-ray, fluoroscopes, MRI, and the like, that can discern the shape and/or location of imaging markers, such as radiopaque markers. In certain embodiments, the medical procedure guide 1910 may contain markers spaced at known intervals that are visible with the imaging devices.
In some implementations, imaging markers 2010 can be located at particular known depths within the medical procedure guide 1910 to facilitate completion of the medical procedure. This is illustrated in
In other implementations, medical procedure guide 1910 can include imaging markers 2020 oriented across the face of guide 1910, or at a common depth. As shown in
These imaging markers 2010 (which may be radiopaque markers) may also include a complementing marker that is visible to the eye. Radiopaque markers on or within the medical procedure guide may also be configured to be visible only in certain x-ray or fluoroscopy orientations. For example, certain radiopaque markers can be seen predominantly in a sagittal view, while others radiopaque markers can be predominantly viewed while in an AP (anterior-posterior) view. Such orientation specific radiopaque markings can ensure that medical procedure guide 1910 is properly oriented, but can also provide the ability to obtain positional and thickness measurements for the physician. For example, using medical procedure guide 1910 with x-ray or fluoroscopy, the physician can visualize the rib spacing, the presence or absence of interposed lung, the distance between the posterior surface of the sternum and the pericardium, the distance between the sternal margin to the thoracic vein or artery, and the patient's sternum thickness. Having this information, the physician can then determine the ideal intercostal spaces for insertion and ultimate placement and orientation of a lead. As another example, the medical procedure guide 1910 may include critical anatomy markings or facilitate the location critical anatomy to avoid damage during a medical procedure.
The medical procedure guide 1910 may be used with x-ray or fluoroscopy to obtain measurements for the thickness of the subcutaneous tissue between the surface of the skin and the anterior surface of the sternum. With these measurements, the physician can then determine whether the pulse generator will fit well over the sternum, or if other anatomical locations described above are better suited for the pulse generator placement. Additionally, using the medical procedure guide 1910 to obtain measurements related to the thickness of the sternum, the physician can calculate the minimum insertion depth that is necessary to obtain the entry point into the intracostal space. The physician can additionally determine the insertion depth that is necessary for the particular insertion technique (e.g., surgical, percutaneous, etc.) or lead delivery system, as described in detail below.
In one implementation, the medical procedure guide 1910 may consist of a flexible material where the skin facing side of the medical procedure guide 1910 includes a means for temporarily and reversibly adhering to the patient's skin. The medical procedure guide 1910 is positioned in the desired location as described earlier and then adhered to the patient's skin. When viewed under x-ray or fluoroscopy, the caretaker can then determine the desired rib space for lead insertion (for example, above the ventricle) and directly correlate the insertion point with the unique marker on the medical procedure guide 1910.
The medical procedure guide 1910 can be a non-sterile tool that can be used prior to sterile preparation of the patient for identifying the proper insertion point. Medical procedure guide 1910 may include any of the aforementioned alignment markings, procedure markings or imaging markers and each may be used to identify particular important locations for a medical procedure. Medical procedure guide 1910 may be designed so that the locations can be identified, for example, by puncturing through guide 1910 and thereby marking the patient, or alternatively by making markings on the patient adjacent to guide 1910, or within openings in guide 1910. Medical procedure guide 1910 may consist of a thin sterile barrier material, that once properly oriented, is placed on the patient within the sterile field. The medical procedure guide 1910 is adhered to the patient's skin and can remain in place throughout the lead insertion process. In this application, the medical procedure guide 1910 material has properties allowing for an incision by scalpel, needle or the like, to be made directly through the medical procedure guide 1910's sterile barrier material. As described above, the sterile barrier medical procedure guide 1910 may contain unique visible and radiopaque markers to assist with placement, orientation, and lead insertion.
Advancing a lead into a patient can also present the risk of damaging physiological structures of the patient. Sensors may be employed to monitor the characteristics of tissues within the vicinity of the distal end of an advancing lead. Readings from sensors associated with the characteristics of tissues can be compared against known characteristics to determine the type of tissue in the vicinity of the distal end of the advancing lead.
Sensors, such as pH sensors, thermocouples, accelerometers, electrical impedance monitors, and the like, may be used to detect the depth of the distal end of the electrode in the patient. Physiological characteristics of the body change the further a lead ventures into it. Measurements performed by sensors at, or near, the distal end of the advancing lead may facilitate the determination of the type of tissue in the vicinity of the distal end of the lead, as well as its depth into the patient.
Various medical imaging procedures, may be used on a patient to determine the location of the desired positions in the heart for the distal end of the lead(s). This information can be used, in conjunction with sensor readings, of the kind described herein, to determine when the distal end of the lead has advanced to a desired location within the patient.
Components may be used to first create a channel to the desired location for the distal end of the lead. Components can include sheathes, needles, cannulas, balloon catheters and the like. A component may be advanced into the patient with the assistance of sensor measurements to determine the location of the distal end of the component. Once the component has reached the desired location, the component may be replaced with the lead or the lead may be inserted within the component. An example of a component can include an expandable sheath. Once the sheath has been advanced to the desired location, a cannula extending the length of the sheath may be expanded, allowing a lead to be pass through the cannula. The sheath may then be removed from around the lead, leaving the lead in situ with the distal end of the lead at the desired location.
Determination of the final placement of the distal end of a lead is important for the delivery of effective therapeutic electrical pulses for pacing the heart. The present disclosure describes multiple technologies to assist in placement of a lead in the desired location. For example, the use of sensors on the pulse generator, on the distal end of leads, or on delivery components. In addition, when a lead or component is advanced into a patient, balloons may be employed to avoid damaging physiological structures of the patient. Inflatable balloons may be disposed on the distal end of the lead or component, on the sides of a lead body of the lead, or may be circumferentially disposed about the lead body. The balloons may be inflated to facilitate the displacement of tissue from the lead to avoid causing damage to the tissue by the advancing lead. A lead delivery assembly may also be used to facilitate delivery of the lead to the desired location. In some variations, the lead delivery assembly may be configured to automatically deliver the distal end of the lead to the desired location in the patient.
At 704, a region can be chosen for advancing of a lead through intercostal muscles associated with the cardiac notch. The region chosen may be based on the determined location of blood-filled structures of the patient in that region. It is important that damage to blood-filled structures, such as arteries, veins, and the like, is avoided when advancing a lead into a patient.
At 706, a lead can be advanced through the intercostal muscles associated with the cardiac notch of the patient. Care should be taken to avoid damaging important physiological structures. Sensors, of the kind described herein, may be used to help avoid damage to important physiological structures.
At 708, advancement of the lead through the intercostal muscles can be ceased. Advancement may be ceased in response to an indication that the distal end of the lead has advanced to the desired location. Indication that the distal end of the lead is at the desired location may be provided through measurements obtained by one or more sensors of the kind described herein.
The lead advanced through the intercostal muscles associated with the cardiac notch of the patient can be configured to transmit therapeutic electrical pulses to pace or defibrillate the patient's heart.
Also shown in
The distal end 806 of lead 802 can include one or more sensors 810. Sensor(s) 810 can be configured to monitor physiological characteristics of the patient while the distal end 806 of lead 802 is being advanced into the patient. Sensors can be disposed along the length of lead 802. For example, sensor 812 is disposed some distance from the distal end 806. In such example, sensor 812 may reside in the subcutaneous tissue between the anterior surface of the ribcage and the surface of the skin, providing unique sensing from such a location. Such sensors incorporated onto the lead can detect subtle physiological, chemical and electrical differences that distinguish the lead's placement within the desired location, as opposed to other locations in the patient's thoracic cavity.
In some variations, the proximal end 804 of lead 802 may be coupled with pulse generator 102 prior to the distal end 806 of lead 802 being advanced through the intercostal space of the patient. In some variations, the proximal end 804 of the lead 802 may be coupled with pulse generator 102 after the distal end 806 of lead 802 has been advanced to the desired location.
To assist in the placement of the lead, various medical instruments may be used. The medical instruments may be used alone, or in combination with sensors disposed on the lead that is being placed. Medical instruments may be used to help the physician to access the desired location for the placement of a lead and/or confirm that the distal end of the lead has reached the desired location. For example, instruments, such as an endoscope or laparoscopic camera, with its long, thin, flexible (or rigid) tube, light and video camera can assist the physician in confirming that the distal end 806 of lead 802 has reached the desired location within the thoracic cavity. Other tools known to one skilled in the art such as a guidewire, guide catheter, or sheath may be used in conjunction with medical instruments, such as the laparoscopic camera, and may be advanced alongside and to the location identified by the medical instruments. Medical instruments such as a guidewire can be advanced directly to the desired location for the distal end of the lead with the assistance of acoustic sound, ultrasound, real-time spectroscopic analysis of tissue, real-time density analysis of tissue or by delivery of contrast media that may be observed by real-time imaging equipment.
In some variations, the patient may have medical devices previously implanted that may include sensors configured to monitor physiological characteristics of the patient. The physiological characteristics of the patient may change based on the advancement of the lead through the intercostal space of the patient. The previously implanted medical device may have sensors configured to detect movement of the advancing lead. The previously implanted medical device can be configured to communicate this information back to the physician to verify the location of the advancing lead.
Sensors disposed on the lead, such as sensors 810 disposed on distal end 806 of the lead may be used to facilitate the delivery of the lead to the desired location. Sensor(s) 810 can be configured to facilitate determination of a depth of the distal end 806 of lead 802. As described above, the depth of the desired location within the patient can be determined using one or more medical instruments. This can be determined during implantation of the lead 802 or prior to the procedure taking place.
Although sensor(s) 810 is illustrated as a single element in
Sensor(s) 810 can be configured to transmit sensor information during advancement to the desired location. Sensor(s) 810 may transmit signals associated with the monitored physiological characteristics of the tissue within the vicinity of the distal end 806 of the lead 802. In some variations, the signals from sensor(s) 810 may be transmitted to a computing device(s) configured to facilitate placement of the lead 802 in the desired location. In such variations, the computing device(s) can be configured to assess the sensor information individually, or in the aggregate, to determine the location of the distal end 806 of lead 802. The computing device(s) can be configured to present alerts and/or instructions associated with the position of the distal end 806 of lead 802.
In some variations, lead 802 can be first coupled with connection port 124 of pulse generator 102. Signals generated by sensor(s) 810 can be transmitted to a computing device(s) using transceiver 316 in pulse generator 102, as illustrated in
An accelerometer may be used to facilitate delivery of the distal end 806 of lead 802 to the desired location. An accelerometer may be disposed at the distal end 806 of lead 802. The accelerometer may be configured to monitor the movement of the distal end 806 of lead 802. The accelerometer may transmit this information to a computing device or the physician. The computing device, or the physician, can determine the location of the distal end 806 of the lead 802 based on the continuous movement information received from the accelerometer as the lead 802 is advanced into the patient. The computing device or the physician may know the initial entry position for lead 802. The movement information can indicate a continuous path taken by the lead 802 as it advanced into the body of the patient, thereby providing an indication of the location of the distal end 806 of lead 802. Pressure waves from the beating heart may differ as absorption changes within deepening tissue planes. These pressure wave differences may be used to assess the depth of the distal end of the electrode.
The accelerometer can also be configured to monitor acoustic pressure waves generated by various anatomical structures of the body. For example, the accelerometer can be configured to detect acoustic pressure waves generated by the heart or by other anatomical structures of the body. The closer the accelerometer gets to the heart, the greater the acoustic pressure waves generated by the heart will become. By comparing the detected acoustical pressure waves with known models, a location of the distal end 806 of lead 802 can be determined.
Pressure waves or vibrations can be artificially generated to cause the pressure waves or vibrations to traverse through the patient. The pressure waves or vibrations can be generated in a controlled manner. The pressure waves or vibrations may be distorted as they traverse through the patient. The level of type of distortion that is likely to be experienced by the pressure waves or vibrations may be known. The pressure waves or vibrations detected by the accelerometer can be compared to the known models to facilitate determination or verification of the location of the distal end 806 of lead 802.
Different tissues within a body exhibit different physiological characteristics. The same tissues situated at different locations within the body can also exhibit different physiological characteristics. Sensors, disposed on the distal end 806, of lead 802 can be used to monitor the change in the physiological characteristics as the distal end 806 is advanced into the body of the patient. For example, the tissues of a patient through which a lead is advanced can demonstrate differing resistances, physiological properties, electrical impedance, temperature, pH levels, pressures, and the like. These different physiological characteristics, and the change in physiological characteristics, experienced as a sensor traverses through a body can be known or identified. For example, even if the actual degree is not known ahead of time, the change in sensor input when the sensor traverses from one tissue media to another may be identifiable in real-time. Consequently, sensors configured to detect physiological characteristics of a patient can be employed to facilitate determining and verifying the location of the distal end 806 of lead 802.
Different tissues can exhibit different insulative properties. The insulative properties of tissues, or the change in insulative properties of tissues, between the desired entry-point for the lead and the desired destination for the lead can be known. Sensor 810 can include an electrical impedance detector. An electrical impedance detector can be configured to monitor the electrical impedance of the tissue in the vicinity of the distal end 806 of lead 802. The electrical impedance of the tissue monitored by the electrical impedance detector can be compared with the known insulative properties of the tissues between the entry point and the destination, to determine the location of the distal end of lead 802 or a transition from one tissue plane to another may be recognized by a measurable change in the measured impedance.
Varying levels of electrical activity can be experienced at different locations with the body. Electrical signals emitted from the heart, or other muscles can send electrical energy through the body. This electrical energy will dissipate the further it gets from its source. Various tissues will distort the electrical energy in different ways. Sensors configured to detect the electrical energy generated by the heart and/or other anatomical structures can monitor the electrical energy as the lead is advanced. By comparing the monitored electrical energy with known models, a determination or verification of the location of the distal end 806 of lead 802 can be made. The sensors may be configured to identify sudden changes in the electrical activity caused by advancement of the sensor into different tissue planes.
Tissues throughout the body have varying pH levels. The pH levels of tissues can change with depth into the body. Sensor(s) 810 can include a pH meter configured to detect the pH levels of the tissue in the vicinity of the sensor(s) 810 as the sensor(s) advance through the patient. The detected pH levels, or detected changes in pH levels, can be compared with known models to facilitate determination or verification of the location of the distal end 806 of lead 802. The pH meter may be configured to identify sudden changes in the pH level caused by advancement of the meter into different tissue planes.
Different tissues can affect vibration-waves or sound-waves in different ways. Sensor(s) 810 can include acoustic sensors. The acoustic sensors can be configured to detect vibration waves or sound waves travelling through tissues surrounding sensor(s) 810. The vibration waves can be emitted by vibration-emitting devices embedded the lead 802. The vibration waves can be emitted by vibration-emitting devices located on a hospital gurney, positioned on the patient, or otherwise remote from lead 802. Sensor(s) 810 can be configured to transmit detected vibration-wave information to a computing device configured to determine the location of the distal end 806 of lead 802 based on the detected vibration-wave information.
Different tissues can have different known effects on the emitted electromagnetic waves. Sensors can be used to detect the effect that the tissue in the vicinity of the sensors have on the electromagnet waves. By comparing the effect that the tissue has on the electromagnetic waves with known electromagnetic effects, the identity of the tissue can be obtained and the location of the lead can be determined or verified. For example, sensor(s) 810 can include electromagnetic wave sensors. Electromagnetic wave sensors can include an electromagnetic wave emitter and an electromagnetic wave detector. The electromagnetic waves will be absorbed, reflected, deflected, and/or otherwise affected by tissue surrounding sensor(s) 810. Sensor(s) 810 can be configured to detect the change in the reflected electromagnetic waves compared to the emitted electromagnetic waves. By comparing the effect the tissue in the vicinity of the sensor(s) 810 has on the electromagnetic waves with known models, a determination verification of the location of lead 802 can be made. The sensors may be configured to identify sudden changes in the electromagnetic activity caused by advancement of the sensor into different tissue planes.
Delivery system 902 can facilitate placement of the distal end of a lead, such as lead 802 illustrated in
At 914, light source 908 can be activated. Light source 908 may emit light-waves into the tissue in the general direction of the intended advancement of delivery system 902. At 916, the tissue can absorb a portion of the emitted light waves. At 918, light detector 910 can detect the reflected light waves, reflected by tissues surrounding light source 908. At 920, a determination of a change in the absorption of the light waves by tissues surrounding the distal tip 906 of delivery system 902 can be made.
At 922, in response to an indication that the absorption of light waves has not changed, delivery system 902 can be configured to advance a delivery system, such as delivery system 902, into the patient. In some variations, a physician can advance delivery system 902 into the patient. In other variations, the delivery system 902 can be advanced into the patient automatically.
At 924, in response to an indication that the absorption of light waves has changed, an alert can be provided to the physician. In some variations, the alert can be provided to the physician through a computing device configured to facilitate positioning of delivery system 902 into the patient.
In some variations, a computing device may be configured to facilitate positioning of delivery system 902 into the patient. The computing device can be configured to alert the physician to the type of tissue in the vicinity of distal tip 906 of delivery system 902. In some variations, the computing device can be configured to alert the physician when the distal tip 906 reaches a tissue having characteristics consistent with the desired location of the distal tip 906 of delivery system 902. For example, when the characteristics of the tissue in the vicinity of the distal tip 906 match those within the intercostal tissues, or a particular location within the medistiunum, an alert may be provided.
Blood vessels, both venous and arterial, absorb red, near infrared and infrared (IR) light waves to a greater degree than surrounding tissues. When illuminating the surface of the body with red, near infrared and infrared (IR) light waves, blood rich tissues, for example veins, will absorb more of this light than other tissues, and other tissues will reflect more of this light than the blood rich tissues. Analysis of the pattern of reflections can enable the blood rich tissues to be located. A positive or negative image can be projected on the skin of the patient at the location of the vein. In some variations, the vein can be represented by a bright area and the absence of a vein can be represented as a dark area, or vice versa.
Delivery system 902 can include a subcutaneous visualization enhancer. The subcutaneous visualization enhancer may be configured to enhance visualization of veins, arteries, and other subcutaneous structures of the body. The subcutaneous visualization enhancer can include moving laser light sources to detect the presence of blood-filled structures, such as venous or arterial structures below the surface of the skin. The subcutaneous visualization enhancer can include systems configured to project an image onto the surface of the skin that can show an operator the pattern of the detected subcutaneous blood-filled structures. Laser light from laser light sources can be scanned over the surface of the body using mirrors. A light detector can be configured to measure the reflections of the laser light and use the pattern of reflections to identify the targeted blood rich structures.
Such subcutaneous visualization enhancers can be used to facilitate determination of the location for the initial approach for inserting a lead, such as lead 802, through the intercostal space associated with the cardiac notch of the patient. In some variations, the visualization enhancers can be disposed remote from the delivery system and/or can be configured to enhance visualization enhancers disposed on the delivery system.
With the provision of a visualization of the detected subcutaneous structures, the physician can assess the position of subcutaneous structures such as the internal thoracic artery, or other structures, of the body while concurrently inserting components of the delivery system into the body, while avoiding those subcutaneous structures.
In some variations, during advancement of lead 802 through the intercostal space associated with the cardiac notch, sensor(s) 810 can be configured to transmit obtained readings to a computing device for interpretation. In some variations, the computing device is pulse generator 102. In some variations, pulse generator 102 is used to transmit the readings to an external computing device for interpretation. In any event, the sensor information from the various sensors can be used individually, or accumulatively, to determine the location of the distal end of lead 802.
Delivery control system 1000 can be configured to receive a plurality of inputs. The inputs can come from one or more sensors disposed in, or on, the patient. For example, delivery control system 1000 can be configured to receive subcutaneous structure visualization information 1002, information associated with delivery insertion systems 1004, information associated with sensors 1006, and the like.
Delivery control system 1000 can be configured to use remote sensors 1006 to facilitate determination of the insertion site for the lead. Sensors 1006 can be disposed in various instruments configured to be inserted into the patient. Sensors 1006 can also be disposed in various instruments configured to remain external to the patient.
Delivery control system 1000 can be configured to perform depth assessments 1008. The depth assessments 1008 can be configured to determine the depth of the distal end of an inserted instrument, such as a lead 802 illustrated in
Depth assessments 1008 can be configured to determine the depth of the delivery system, or lead, though pressure wave analysis systems 1012. Pressure waves can be detected by accelerometers as herein described.
Depth assessments 1008 can be configured to determine the depth of the delivery system though acoustic analysis systems 1014. Acoustic analysis system 1014 can be configured to operate in a similar manner to a stethoscope. The acoustic analysis system 1014 can be configured to detect the first heart sound (S1), the second heart sound (S2), or other heart sounds. Based on the measurements obtained by the acoustic analysis system 1014, a depth and/or location of the distal end of a delivery system and/or inserted medical component can be determined. The acoustic analysis system 1014 can be configured to measure the duration, pitch, shape, and tonal quality of the heart sounds. By comparing the duration, pitch, shape, and tonal quality of the heart sounds with known models, a determination or verification of the location of the lead can be made. Sudden changes in the degree of heart sounds may be used to indicate advancement into a new tissue plane.
In some variations, the lead can include markers or sensors that facilitate the correct placement and orientation of the lead. Certain markers such as a visual scale, radiopaque, magnetic, ultrasound markers, and the like, can be position at defined areas along the length of the lead so that the markers can be readily observed by an implanting physician, or automated system, on complementary imaging instruments such as fluoroscopy, x-ray, ultrasound, or other imaging instruments known in the art. Through the use of these markers, the physician, or automated implantation device, can guide the lead to the desired location within the intercostal muscle, pleural space, mediastinum, or other desired position, as applicable, and also ensure the correct orientation.
Avoiding damage to tissues in the vicinity of the path-of-travel for the lead is important. Moving various tissues from the path of the lead without damaging them is also important.
Having leads directly touch the tissue of a patient can be undesirable and can damage the tissue. Consequently, the distal tip 1104 of lead 802 can include an inflatable balloon 1108. Balloon 1108 can be inflated when the distal tip 1104 of lead 802 encounters an anatomical structure obstructing its path, or prior to moving near sensitive anatomy during lead delivery. The balloon may be configured to divert the obstacle and/or the lead to facilitate circumventing the anatomical structure or may indicate that the lead has reached its intended destination.
To inflate the balloon, lead 802 can include a gas channel 1110. At the end of gas channel 1110 there can be a valve 1112. Valve 1112 can be controlled through physical manipulation of a valve actuator, through electrical stimulation, through pressure changes in gas channel 1110 and/or controlled in other ways. In some variations, the valve 1112 may be configured at the proximal end of the lead 802.
When positioning lead 802 into a patient, lead 802 may cause damage to, or perforations of, the soft tissues of the patient. When lead 802 is being installed into a patient, distal tip 1104 of lead 802 can encounter soft tissue of the patient that should be avoided. In response to encountering the soft tissue of the patient, gas can be introduced into gas channel 1110, valve 1112 can be opened and balloon 1108 can be inflated, as shown in
In some variations, a delivery component or system is used to facilitate delivery of a lead, such as lead 802, to the desired location.
Tip 1204 can include one or more sensors for facilitating the placement of the lead. The sensors included in tip 1204 of the expandable sheath 1202 can be the same or similar to the sensors described herein for monitoring physiological characteristics of the body and other characteristics for facilitating positioning of a lead in a body.
Expandable sheath 1202 can include a channel 1206 running through a hollow cylinder 1208 of expandable sheath 1202. When tip 1204 of expandable sheath 1202 is at the desired location, gas or liquid can be introduced into hollow cylinder 1208. The gas or liquid can be introduced into hollow cylinder 1208 through a first port 1210. Hollow cylinder 1208 can expand, under the pressure of the gas or liquid, causing channel 1206 running through hollow cylinder 1208 to increase in size. A lead, such as lead 802 illustrated in
Using expandable sheath 1202 can provide an insertion diameter smaller than the useable diameter. This can facilitate a reduction in the risk of damage to tissues and vessels within the patient when placing the lead.
When electricity is brought within the vicinity of muscle tissue, the muscle will contract. Consequently, having a lead for carrying electrical pulses traversing through intercostal muscle tissue may cause the intercostal muscle tissue to contract. Electrical insulation can be provided in the form of a receptacle disposed in the intercostal muscle, where the receptacle is configured to electrically insulate the intercostal muscle from the lead.
The intercostal space 1302 is the space between two ribs, for example, rib 1306a and rib 1306b. Intercostal muscles 1308a, 1308b and 1308c can extend between two ribs 1306a and 1306b, filling intercostal space 1302. Various blood vessels and nerves can run between the different layers of intercostal muscles. For example, intercostal vein 1310, intercostal artery 1312, the intercostal nerve 1314 can be disposed under a flange 1316 of upper rib 1306a and between the innermost intercostal muscle 1308c and its adjacent intercostal muscle 1308b. Similarly, collateral branches 1318 can be disposed between the innermost intercostal muscle 1308c and its adjacent intercostal muscle 1308b.
The endothoracic facia 1320 can abut the inner-most intercostal muscle 1308c and separate the intercostal muscles from the parietal pleura 1322. The pleural cavity 1324 can be disposed between the parital pleura 1322 and the visceral pleura 1326. The visceral pleura 1326 can abut the lung 1328.
Lead receptacle 1304 may comprise a cylindrical body, or lumen 1328, from an outer side of an outermost intercostal muscle to an inner side of an innermost intercostal muscle of an intercostal space. Lumen 1328 may be configured to support a lead traversing through it. Lumen 1328 may comprise an electrically insulating material configured to inhibit traversal of electrical signals through walls of lumen 1328. In some variations, end 1336 of the receptacle 1304 may pass through the innermost intercostal muscle 1308c. In some variations, end 1338 of receptacle 1304 can pass through outermost intercostal muscle 1308a.
Lumen 1328 can terminate adjacent the pleural space 1324. In some variations, the lumen 1328 can terminate in the mediastinum. In some variations, receptacle 1304 can be configured to be screwed into the intercostal muscles 1308a, 1308b, and 1308c. Receptacle 1304 can also be configured to be pushed into the intercostal muscles 1308a, 1308b and 1308c.
Lead receptacle 1304 may include a fixation flange 1330a. Fixation flange 1330a may be disposed on the proximal end of the lumen 1328 and configured to abut the outermost intercostal muscle 1308a. Lead receptacle 1304 may include a fixation flange 1330b. Fixation flange 1330b can be disposed on the distal end of the lumen 1328 and configured to abut the outermost intercostal muscle 1308c. Lead receptacle 1304 can be implanted into the intercostal muscles 1308a, 1308b, and 1308c by making an incision in the intercostal muscles 1308a, 1308b, and 1308c, stretching the opening and positioning lead receptacle 1304 into the incision, taking care to ensure that the incision remains smaller than the outer diameter of flanges 1330a and 1330b. In some variations flanges 1330a and 1330b can be configured to be retractable allowing for removal and replacement of the lead fixation receptacle 1304.
Lead receptacle 1304 can be fixed in place by using just flanges 1330a and 1330b. Lead receptacle 1304 may also be fixed in place by using a plurality of surgical thread eyelets 1332. Surgical thread eyelets 1332 can be configured to facilitate stitching lead receptacle 1304 to the intercostal muscles 1308a and 1308c to fix lead receptacle 1304 in place.
Receptacle 1304 can include an internal passage 1334. Internal passage 1334 can be configured to receive one or more leads and facilitate their traversal through the intercostal space 1302.
Lead receptacle 1304 can be formed from an electrically insulating material. The electrically insulating material can electrically isolate the intercostal muscles 1308a, 1308b and 1308c from the leads traversing through lead receptacle 1304.
Lead receptacle 1304 can be formed from materials that are insulative. The material can include certain pharmacological agents. For example, antibiotic agents, immunosuppressive agents to avoid rejection of lead receptacle 1304 after implantation, and the like. In some variations, lead receptacle 1304 can be comprised of an insulative polymer coated or infused with an analgesic. In some variations, the lead receptacle 1304 can be comprised of an insulative polymer coated or infused with an anti-inflammatory agent. The polymer can be coated or infused with other pharmacological agents known to one skilled in the art to treat acute adverse effects from the implantation procedure or chronic adverse effects from the chronic implantation of the lead or receptacle within the thoracic cavity.
In some variations, the lead receptacle can comprise multiple lumens. For example, lead receptacle can comprise a second lumen configured to traverse from an outermost side of an outermost intercostal muscle to an innermost side of an innermost intercostal muscle. Second lumen can be configured to facilitate dispensing of pharmacological agents into the thorax of the patient.
The lumens for such a lead receptacle can be used for differing purposes in addition to the passage of a single lead into the pleural space or mediastinum. The multiple lumens can provide access for multiple leads to be passed into the pleural space or mediastinum.
The lead receptacle as described with reference to
In some variations, the lead receptacle can be actively fixed into position using one end of the lead receptacle. For example, only one flange can include surgical thread holes to facilitate sewing of the flange into the intercostal muscles.
Active fixation, whether at flanges, or along the lumen of the lead fixation receptacle, can include, for example, the use of tines, hooks, springs, screws, flared wings, flanges and the like. Screws can be used to screw the lead fixation receptacle into bone or more solid tissues within the thoracic cavity. Hooks, tines, springs, and the like, can be used to fix the lead fixation receptacle into soft tissues within the thoracic cavity.
In some variations the lead receptacle can be configured to facilitate in-growth of tissue into the material of which the lead fixation receptacle is comprised. For example, the lead fixation receptacle can be configured such that bone, cartilage, intercostal muscle tissue, or the like, can readily grow into pockets or fissures within the surface of the lead receptacle. Facilitating the growth of tissue into the material of the lead receptacle can facilitate fixation of the receptacle.
In some variations, the receptacle can be configured to actively fix between layers of the intercostal muscle. With reference to
Sensing and detection will be performed using one or more available signals to determine when pacing should be delivered or inhibited. Cardiac signals will be measured from one or more electrodes. Additional non-cardiac sensors may also be used to enhance the accuracy of sensing and detection. Such sensors include, but are not limited to rate response sensors, posture/positional sensors, motion/vibration sensors, myopotential sensors and exogenous noise sensors. One or more algorithms will be utilized to make decisions about pacing delivery and inhibition. Such algorithms will evaluate available signal attributes and relationships, including but not limited to analysis of morphology, timing, signal combinations, signal correlation, template matching or pattern recognition.
A pulse generator, such as pulse generator 102 illustrated in
Sensor(s) can be configured to detect an activity of the patient. Such activity sensors can be contained within or on the housing of the pulse generator, such as pulse generator 102 illustrated in
In some variations, an activity sensor can include an accelerometer. The accelerometer can be configured to detect accelerations in any direction in space. Acceleration information can be used to identify potential noise in signals detected by other sensor(s), such as sensor(s) configured to monitor the physiological characteristics of the patient, and the like, and/or confirm the detection of signals indicating physiological issues, such as arrhythmias or other patient conditions.
In some variations, a lead, such as lead 802 in
In some variations, sensors, such as sensors 810 and 812 of
A lead disposed in the body of a patient, such as lead 802 of
Additional leads may be used to facilitate an increase in the sensing capabilities of the implantable medical device. In one embodiment, in addition to at least one lead disposed within the intercostal muscle, pleural space or mediastinum, another lead is positioned subcutaneously and electrically connected to the implantable medical device. The subcutaneously placed lead can be configured to enhance the implantable medical device's ability to sense and analyze far-field signal's emitted by the patient's heart. In particular, the subcutaneous lead enhances the implantable medical device's ability to distinguish signals from particular chambers of the heart, and therefore, appropriately coordinate the timing of the required pacing therapy delivered by the implantable medical device.
Additional leads in communication with the implantable medical device or pulse generator, and/or computing device, can be placed in other areas within the thoracic cavity in order to enhance the sensing activity of the heart, and to better coordinate the timing of the required pacing therapy delivered by the implantable medical device. In certain embodiments, these additional leads are physically attached to the implantable medical device of the present disclosure.
The leads used to deliver therapeutic electrical pulses to pace the heart can comprise multiple poles. Each pole of the lead can be configured to deliver therapeutic electrical pulses and/or obtain sensing information. The different leads can be configured to provide different therapies and/or obtain different sensing information. Having multiple sensors at multiple locations can increase the sensitivity and effectiveness of the provided therapy.
The different end-leads 818a, 818b, 818c, can include different electrodes and/or sensors. For example, end-lead 818b can include an electrode 808b at the distal end 806b of end-lead 818b that differs from electrode 808a at distal end 806a of end-lead 818a. Electrode 808b can have flanges 820. Flanges 820 can be configured to act as an anchor, securing the distal end 806b of end-lead 818b in position within the patient. Electrode 808b with flanges 820 can be suitable for anchoring into high-motion areas of the body where end-lead 818b would otherwise move away from the desired location without the anchoring effect provided by flanges 820. Similarly, electrode 808c at the distal end 806c of end-lead 818c can be configured for a different function compared to the electrodes at the end of other end-leads.
Lead 802 can be a multi-pole lead. Each pole can be electronically isolated from the other poles. The lead 802 can include multiple isolated poles, or electrodes, along its length. The individual poles can be selectively activated. The poles may include sensors for monitoring cardiac or other physiological conditions of the patient, or electrodes for deliver therapy to the patient.
The sensing characteristics of a patient can change over time, or can change based on a patient's posture, a multi-pole lead permits the implantable medical device facilitate monitoring a patient's state through multiple sensing devices, without requiring intervention to reposition a lead. Furthermore, a multi-pole lead can be configured to facilitate supplementary sensing and therapy delivery vectors, such as sensing or stimulating from one pole to a plurality of poles, sensing or stimulating from a plurality of poles to a single pole, or sensing or stimulating between a plurality of poles to a separate plurality of poles. For example, should one particular vector be ineffective at treating a particular arrhythmia, the implantable medical device, or pulse generator, can be configured to switch vectors between the poles on the lead and reattempt therapy delivery using this alternative vector. This vector switching is applicable for sensing. Sensing characteristics can be monitored, and if a sensing vector becomes ineffective at providing adequate sensing signals, the implantable medical device can be configured to switch vectors or use a combination of one or more sensor pairs to create a new sensing signal.
In some variations, at yoke 816, each of the poles of the multi-pole lead can be split into their separate poles. Each of the end-leads emanating from the yoke 816 can be associated with a different pole of the multi-pole lead.
Some of the end-leads emanating from yoke 816 can be configured for providing sensor capabilities of and/or therapeutic capabilities to the patient's heart. Others of the end-leads emanating from yoke 816 can be configured to provide sensor capabilities and/or therapeutic capabilities that are unrelated to the heart. Similarly, the cardiac pacing system herein described can include leads 802, or medical leads, that provide functionality unrelated to the heart.
In some variations, the lead can be bifurcated. A bifurcated lead can comprise two cores within the same lead. In some variations, the different cores of the bifurcated lead can be biased to bend in a predetermined manner and direction upon reaching a cavity. Such a cavity can, for example, be the mediastinum. Bifurcated lead cores can be comprised of shape memory materials, for example, nitinol or other material known in the art to deflect in a predetermined manner upon certain conditions. The conditions under which the bifurcated lead cores will deflect include electrical stimulation, pressure, temperature, or other conditions. In some variations, each core of the bifurcated lead can be configured so that it is steerable by the physician, or an automated system, to facilitate independent advancement of each core of the bifurcated lead, in different directions.
In some variations, sensors from the cardiac pacing system may be selected to optimize sensing characteristics of the cardiac signals. Sensing signals, comprised from one or more sensor pairs may be selected via manual operation of the programming system or automatic operation of the implanted cardiac pacing system. Sensing signals may be evaluated using one of several characteristics including signal amplitude, frequency, width, morphology, signal-to-noise ratio, and the like.
The cardiac pacing system can be configured to use multiple sensors to generate one or more input signals, optionally apply filtering of varying levels to these signals, perform some form of verification of acceptance upon the signals, use the signals to measure levels of intrinsic physiological activity to, subsequently, make therapy delivery decisions. Methods to perform such activities in part or in total include hardware, software, and/or firmware based signal filters, signal amplitude/width analysis, timing analysis, morphology analysis, morphological template comparison, signal-to-noise analysis, impedance analysis, acoustic wave and pressure analysis, or the like. The described analyses may be configured manually via the programming system or via automatic processes contained with the operation software of the cardiac pacing system.
As previously discussed, placing the distal end of the pacing lead in the proper location is important for successful monitoring of a patient's heart and for efficient delivery of therapy. Furthermore, during placement of the lead, a physician must avoid damaging important blood vessels and other anatomical structures of the patient. The provision of a stable platform from which to deliver the leads can reduce the likelihood of collateral damage to anatomical structures of the patient. However, if a delivery platform is remote from the patient, the patient can move relative to the platform. The present disclosure describes a lead delivery system configured for placement on an anatomical structure of the patient, thereby reducing the risk of altering the relative location between the delivery system and the patient during delivery. When the term lead delivery system is used in the present disclosure, it is contemplated that such may also be capable of delivering components other than leads, for example, the lead delivery system may also be utilized in conjunction with delivery assist components. The lead delivery system may also be referred to as a component delivery system.
Lead delivery system 1702 can be configured to be affixed to a patient at a desired location such that it remains stationary relative to the patient. Stable fixation to the patient provides an additional benefit where multiple medical instruments are used in concert with lead delivery system 1702. For example, if a device for assisting in lead delivery is first inserted into delivery system 1702 prior to insertion of the lead itself, the physician will have increased confidence that the system did not move between insertion of the two devices. Optionally, lead delivery system 1702 can be handheld and not affixed to the patient.
Lead delivery system 1702 may include base 1712 and lead delivery device 1714. Base 1712 can be configured to secure lead delivery device 1714 to one or more anatomical structures of the patient. In some variations, lead delivery system 1702 can be secured to an anatomical structure of the patient by use of an adhesive. For example, base 1712 can include an adhesive pad. In some variations, an adhesive pad can be reversibly secured to the patient. Proper placement of the adhesive pad to the patient can be accomplished based upon well-known anatomical landmarks, by imaging equipment, or the like.
Lead delivery system 1702 may also be secured to the patient by way of a screw mechanism that securely, but reversibly, affixes lead delivery system 1702 to bone, cartilage or other material within the patient's body.
In some variations, base 1712 of lead delivery system 1702 can include a clamp 1704. Clamp 1704 can be configured to secure base 1712 to the patient. Clamp 1704 can be configured to secure lead delivery device 1714 to one or more anatomical structures of the patient. Clamp 1704 can include a movable clamp platform 1706 and a stationary platform 1715. A hook portion 1708 can be disposed at one end of clamp platform 1706. Hook portion 1708 can be configured to engage with a known anatomical region of the patient. For example, hook portion 1708 can be configured to extend or retract to forcibly engage with the edge of the patient's sternum, while the opposite edge of the patient's sternum engages with stationary platform 1715. At least a portion of clamp platform 1706 may rest on the sternum of the patient. In some variations, the patient's sternum will be exposed, and clamp 1704 can be secured directly to the sternum. In some variations, clamp platform 1706 can include an adhesive portion configured to be disposed between a clamp platform 1706 and the patient to cause clamp platform 1706 to stick to the patient.
In some variations, clamp 1704 can be configured to clamp onto a single rib, multiple ribs, the xyphoid, or other anatomical structures. Clamp 1704 can be engaged around any portion of the chosen anatomical structure. For example, clamp 1704 can be configured to clamp on to the sides of an anatomical structure. In some variations, clamp 1704 can be configured to clamp on the top and bottom of an anatomical structure. In some variations, clamp 1704 can be configured to engage outwardly to secure lead delivery system 1702 between two anatomical structures. When secured to two anatomical structures, lead delivery system 1702 can be secured by expansion forces exerted by clamp 1704 outwardly from clamp platform 1706, against the two anatomical structures. For example, clamp 1704 can be configured to facilitate exerting an outward pressure against two ribs of the patient. The resultant force exerted back against clamp 1704 can keep clamp 1704 in place, relative to the patient.
Clamp 1704 can be tightened when clamp 1704 has been positioned on, around, and/or between the intended anatomical structure(s). In some variations, a screw, an adjustable latch, a ratcheting mechanism, or the like, can be used to adjust clamp 1704. The pressure of clamping clamp 1704 on the anatomical structure may be adjusted with an adjustment handle 1720. Adjustment handle 1720 can also be configured to make adjustments, or refinements, to the location of lead delivery system 1702 as it may become necessary to fine tune the position of lead delivery system 1702 after it has been secured to an anatomical structure of the patient.
As previously noted, it is important to avoid certain critical structures and vessels during lead delivery, such as the heart, lungs, pericardium, internal thoracic artery, and other major vessels of the anterior thoracic region. Exemplary lead delivery system 1702, depicted in
Lead delivery devices and systems of the present disclosure are not required to have a clamp 1704, as depicted in
In one implementation, such a distal end may be configured to puncture the tissue, for example with a relatively blunt access tip, to facilitate entry into the intercostal space without requiring a surgical incision to penetrate through the intercostal muscles. A blunt access tip, while providing the ability to puncture and push through tissue, does not cut, thereby reducing the potential for damage to the pericardium or other internal organs the tip may contact should such contact occur.
Lead delivery systems configured for lead insertion proximate the lateral margin of the sternum may optionally be designed to effect lead placement to a substernal location. For example, a distal end of the lead delivery system may be shaped or curved, or may be articulable to move after passing the sternum. Alternatively, the lead itself may be articulable in a similar manner.
When lead delivery systems 1702 are configured to be pressed against the sternum of the patient, slid across the sternum until reaching the lateral margin, and then dropped down through the intercostal tissue immediately lateral to the sternal margin, this process may be utilized after a physician has made an incision above the sternum. Such an incision may have been made, for example, to insert a pulse generator, as previously described. In such cases, the lead delivery system may easily traverse the sternum prior to puncturing the intercostal muscles and creating a path to the mediastinum for insertion of lead(s). Proper lead delivery system and lead insertion depth determinations in such cases are facilitated by the fact that sternum and rib cage thicknesses are similar across patient populations. As such, the insertion depth of the lead delivery system may be set at a nominal sternum thickness or slightly less, and thereafter be adjusted deeper to ensure that the lead delivery system does not extend too far within the mediastinum. However, in some cases, lead delivery systems may be utilized in a percutaneous manner, without an incision above the sternum (or without an incision at other entry locations described herein). In these cases, the thickness of a patient's subcutaneous tissue must be accounted for.
Numerous methods for proper lead depth determination have been described herein including systems, methods and software for automating the lead delivery process. These and other implementations may be modified to further account for subcutaneous tissue thickness estimations. In one example, an implanting physician may assess the thickness of subcutaneous tissue based upon specific patient attributes such as height, weight, sex, waist size, chest size, sternum length, etc. These patient attributes may be assessed individually or in combination to predict subcutaneous tissue thickness. Alternatively, direct measurement of the subcutaneous tissue thickness may be made by means such as a needle probe, ultrasound, CT scan, MRI, or the like. Information related to items such as the distance between the posterior surface of the sternum and the pericardium, the distance between the sternal margin to the thoracic vein or artery, and sternum thickness may then be used by the physician, or by an automated delivery system, to adjust the intended lead implantation location, orientation and depth.
With further reference to
Leads delivered by lead delivery system 1702 may be leads configured to deliver therapeutic electrical pacing to the heart of the patient. Leads delivered by lead delivery system 1702 can also be leads configured to obtain physiological information about the patient, such as heart function, lung function, the performance of various blood vessels, and the like.
Lead delivery device 1714 can be configured to advance a lead through an intercostal space of the patient and, optionally, into the mediastinum of the patient. Lead delivery device 1714 can be configured to position the distal end of the lead at any of the positions described in the present disclosure. Lead delivery device 1714 can also be configured to control an angle at which a lead is inserted into the patient.
Lead delivery system 1702 can include a cannula 1716, which may extend through the length of lead delivery device 1714. Cannula 1716 can also extend through the lead advancer. Cannula 1716 can be configured to receive a lead for insertion and may be configured to accompany a lead as it is inserted into the patient. In some variations, cannula 1716 can be configured to receive delivery assist components (discussed below) for insertion into the patient. In some variations, lead delivery system 1702 can include multiple cannulas for simultaneous delivery of leads and/or delivery assist components into the patient.
In some variations, a screw, an adjustable latch, a ratcheting mechanism, or the like, can be used to adjust the distance between the distal end 1713 of cannula 1716 and stationary platform 1715. Such adjustments or refinements may become necessary to fine tune the position of lead delivery system 1702 and the location of the distal end 1713 of cannula 1716 after it has been secured to an anatomical structure of the patient
In some instances, a smaller cannula opening may ease the insertion through tissue. As such, in additional variations, the size of the cannula opening may be variably controlled by the operator. The cannula may, for example, be comprised of two cannula halves, or multiple cannula segments, that expand or separate to a desired opening size. The variably selected cannula opening size may be controlled via screw, an adjustable latch, a ratcheting mechanism, lever, or the like, in order to facilitate delivery of a variety of lead shapes and sizes.
Lead delivery system 1702 may utilize delivery assist component(s) such as a needle, a guide wire, guide catheter, sheath, expandable catheter, balloon catheter and the like. A delivery assist component can be configured to facilitate delivery of a lead into the patient. Delivery assist components may be configured to be inserted into a patient and advanced to the desired location prior to lead insertion. Alternatively, a delivery assist component can be configured to be inserted into the patient with a lead and advanced with the lead to the desired location. The delivery assist component can be used to create space and minimize damage to surrounding tissue prior to, or in connection with, the deployment of a lead into the patient. The delivery assist component can be removed from the patient once the lead has been placed at the desired location. Delivery assist components can be inserted into the patient by the lead delivery system 1702 in much the same way as a lead. Delivery assist components may incorporate sensors. Such sensors can include the sensor types described in the present disclosure for use on leads to monitor the location of leads with respect to patient anatomy. It is understood that delivery assist components may interact with lead delivery system 1702 in much the same way as leads themselves, as described herein.
Careful advancement of the component into the patient is desirable. Lead delivery system 1702 can include a lead advancer, which can be configured to incrementally advance a lead into a patient in response to an interaction by an operator. Limiting movement of the lead advancing into the body can avoid accidental perforation and damage to anatomical structures. In some variations, lead delivery system 1702 can include a trigger 1724, which can be configured to activate a ratcheting mechanism to advance the lead. One pull on trigger 1724 connected to the ratcheting mechanism can cause the lead to be advanced a known, prescribed, amount. For example, the amount can be set to 1 mm, 2 mm, or the like. In some variations, this length can be set or programmed by the physician. In some variations, a partial pull on trigger 1724 can result in a partial advancement of the lead by a partial amount of the set amount. For example, where depressing the trigger fully can result in an advancement of 1 mm and therefore a partial depression of the trigger can be set to cause the result of an advancement of 0.5 mm. The lead delivery system 1702 can include a limit on the number of trigger 1724 pulls permitted within an interval. For example, the lead delivery system 1702 may restrict the physician from pulling trigger 1724 more than one time per second. In another option, the lead delivery system 1702 may require the physician to actively set a trigger limit in order to permit trigger 1724 pulls in excess of the permitted interval.
Lead delivery system 1702 can include a locking mechanism activated by a locking switch 1728 that can reversibly lock a lead with respect to the lead delivery system 1702. When locked, the lead being delivered to the patient can be engaged with delivery system 1702 such that it cannot be moved independent of movement from, say, the ratcheting system. When unlocked, the lead can move freely within cannula 1716 of lead delivery system 1702. Lead delivery system 1702 can be further configured to only permit movement of the lead in one direction when locking switch 1728 is in the unlocked position.
Where a delivery assist component is used and unlocked from lead delivery system 1702, the physician can remove the delivery assist component, such as a needle, from cannula 1716. The physician may then insert another delivery assist component, or a lead, into cannula 1716 of lead delivery system 1702. The physician can lock the lead, or the new delivery assist component, for example, into the ratcheting mechanism of lead delivery system 1702. The physician, or an automated system, can then advance the lead within the patient to a depth indicated by the previous component's readout. In some variations, the physician can use the previous depth readout with sensors or physical markers on the lead to ensure proper placement of the lead.
While the lead is being inserted into the patient to the desired location, the movement of the lead can be metered. Transverse movement of the lead can be metered as well the depth of the lead into the patient. Metering the movement of the lead can avoid excessive movement of the lead. In some variations, movement can be metered by a ratcheting mechanism and the magnitude of the movement of the lead can be presented to the operator. For example, a reading indicating the amount of movement can be presented to the operator, such as through reading window 1722.
In some variations, lead delivery system 1702 can be configured to coordinate with real-time imaging equipment to assess the relative location of the lead being delivered by lead delivery system 1702.
Sensor(s) associated with lead delivery system 1702 can facilitate delivery. Sensor(s) can be disposed on the lead delivery device 1714, remote from the lead delivery device 1714, such as on a gurney, or in an operating room, on the lead itself, or in other locations.
Sensor(s) may be utilized to help determine an appropriate insertion point for the lead by, for example, identifying blood-filled vessels such as arteries and veins below the surface of the skin. An example of such identification of subcutaneous vessels is described in relation to
Sensor(s) can also utilized to determine a proper depth in the patient for the distal end of the lead, or proper positioning with respect to specific anatomy. As previously described, different tissues within the patient's body can demonstrate varying characteristics. The differing physiological characteristics of the tissues of the body can facilitate placement of the delivery system and/or lead at the desired location. Lead delivery system 1702 can be configured to monitor the physiological characteristics of the tissues surrounding the distal end, or advancing end, of the lead and/or delivery assist component being delivered to the desired position. Physiological sensors, such as pressure sensors, impedance sensors, accelerometers, pH sensors, temperature sensors, and the like, can monitor the characteristics of the anatomy at the end of the implanted, or advancing, lead or device. Lead delivery system 1702 can be configured to determine the location of the lead being implanted based on the detected physiological characteristics as has been described with reference to
Lead delivery system 1702 can be configured to provide real-time feedback to an implanting physician based on readings from the above-mentioned sensors. Feedback can be provided with indicators, alarms or the like.
Lead delivery system 1702 can be automated. Automating the lead delivery system can allow a physician to set up the system and then rely on sensors and computer control of lead delivery system 1702 to deliver the lead to the desired location. In some variations, the lead delivery system 1702 can be semi-automatic, where measurements and advancements made by lead delivery system 1702 occur automatically, but only after the physician reviews certain measurements or replies to prompts provided by lead delivery system 1702.
Computing device 1802 can include electronic storage 1806 to store computer-readable instructions for execution by processor(s) 1804. The computer-readable instructions can cause processor(s) 1804 to perform functions consistent with the present disclosure. The functions that can be performed include the functions described herein attributable to a physician.
Sensors disposed on an advancing lead, a delivery assist component, or the lead delivery system 1702 (all referred to as component sensors 1808 in
Computing device 1802 can be in communication with one or more component sensors 1808 and/or external sensors 1810. Computing device 1802 may communicate with such sensors through wired or wireless communication systems. As described throughout the present disclosure, such sensors can be used by computing device 1802 to determine an insertion point that is optimally placed with respect to anatomy such as the sternum, ribs, or critical arteries. The sensors can also be used by computing device 1802 to determine a safe path of advancement and fixation for a lead, which will avoid damage to critical structures and provide optimal distal end placement for effective pacing and sensing. Optimal placement effected by an automated delivery system 1702, in conjunction with computing device 1802 can result in the distal end of a lead being placed in any of the locations described within the present disclosure (for example, intercostally into the mediastinum, or to just beyond the innermost intercostal muscle, etc.).
Computing device 1802 can be further configured to control one or more actuators 1814 disposed on a lead delivery system 1702. The lead delivery system can comprise motors configured to advance or retract a delivery assist component and/or lead, or to effect lateral movements, or to change the angle of advancement or retraction of the lead.
Computing device 1802 and automated lead delivery system can be further configured to present information via indicators, alarms or on a screen associated with the placement of a lead and/or delivery assist component. Computing device 1802 can be in electronic communication with a display 1812. Computing device 1812 can be configured to cause a presentation on display 1812 of information associated with the advancing lead. For example, measurements obtained by sensor(s) 1808 and/or 1810 can be processed by processor(s) 1804 to provide images or representations of anatomy in the vicinity of an advancing lead. Computing device 1802 can be configured to cause presentation of warnings on display 1812. For example, computing device 1802 can be configured to cause an indication to be presented on display 1812 that the end of the lead has reached the desired location within the patient. Display 1812 can display an indication of damage to tissues caused by an advancing lead. Display 1812 can display an indication of future potential damage of tissues allowing the operator to stop the procedure or determine solutions to circumvent problems. In some variations, processor(s) 1804 can be configured to determine solutions to circumvent problems and cause the solutions to be presented on the display 1812.
While components have been described herein in their individual capacities, it will be readily appreciated the functionality of individually described components can be attributed to one or more other components or can be split into separate components. This disclosure is not intended to be limiting to the exact variations described herein, but is intended to encompass all implementations of the presently described subject matter.
In the descriptions above, phrases such as “at least one of” or “one or more of” may occur followed by a conjunctive list of elements or features. The term “and/or” may also occur in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it used, such a phrase is intended to mean any of the listed elements or features individually or any of the recited elements or features in combination with any of the other recited elements or features. For example, the phrases “at least one of A and B;” “one or more of A and B;” and “A and/or B” are each intended to mean “A alone, B alone, or A and B together.” A similar interpretation is also intended for lists including three or more items. For example, the phrases “at least one of A, B, and C;” “one or more of A, B, and C;” and “A, B, and/or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.” Use of the term “based on,” above is intended to mean, “based at least in part on,” such that an unrecited feature or element is also permissible.
The subject matter described herein can be embodied in systems, apparatus, methods, and/or articles depending on the desired configuration. The implementations set forth in the foregoing description do not represent all implementations consistent with the subject matter described herein. Instead, they are merely some examples consistent with aspects related to the described subject matter. Although a few variations have been described in detail above, other modifications or additions are possible. In particular, further features and/or variations can be provided in addition to those set forth herein. For example, the implementations described above can be directed to various combinations and subcombinations of the disclosed features and/or combinations and subcombinations of several further features disclosed above. In addition, the logic flows depicted in the accompanying figures and/or described herein do not necessarily require the particular order shown, or sequential order, to achieve desirable results.
This application is a continuation of and claims priority to and benefit of U.S. patent application Ser. No. 17/581,543, filed Jan. 21, 2022, which is a continuation of and claims priority to and benefit of U.S. patent application Ser. No. 16/453,932, filed Jun. 26, 2019 and issued Jan. 25, 2022 as U.S. Pat. No. 11,229,500, which is a continuation of and claims priority to and benefit of U.S. patent application Ser. No. 15/644,714, filed Jul. 7, 2017 and issued Aug. 18, 2020 as U.S. Pat. No. 10,743,960 which claims priority to and benefit of U.S. Provisional Patent Application 62/360,110, filed Jul. 8, 2016, and is also a continuation in part of U.S. patent application Ser. No. 14/846,578, filed Sep. 4, 2015, which claims priority to and the benefit of U.S. Provisional Patent Application 62/083,516, filed Nov. 24, 2014, U.S. Provisional Patent Application 62/146,569, filed Apr. 13, 2015, and U.S. Provisional Application 62/045,683, filed Sep. 4, 2014, the disclosures of which are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2003007 | Olive | May 1935 | A |
| 3416534 | Quinn | Dec 1968 | A |
| 3485247 | Ackerman | Dec 1969 | A |
| 4030509 | Heilman | Jun 1977 | A |
| 4146037 | Flynn | Mar 1979 | A |
| 4270549 | Heilman | Jun 1981 | A |
| 4280510 | ONeill | Jul 1981 | A |
| 4291707 | Heilman | Sep 1981 | A |
| 4306560 | Harris | Dec 1981 | A |
| 4408604 | Hirshorn | Oct 1983 | A |
| 4437475 | White | Mar 1984 | A |
| 4502492 | Bornzin | Mar 1985 | A |
| 4512351 | Pohndorf | Apr 1985 | A |
| 4532931 | Mills | Aug 1985 | A |
| 4538624 | Tarjan | Sep 1985 | A |
| 4636199 | Victor | Jan 1987 | A |
| 4649937 | DeHaan | Mar 1987 | A |
| 4664120 | Hess | May 1987 | A |
| 4765341 | Mower | Aug 1988 | A |
| 4784161 | Skalsky | Nov 1988 | A |
| 4787389 | Tarjan | Nov 1988 | A |
| 4832687 | Smith, III | May 1989 | A |
| 4846191 | Brockway | Jul 1989 | A |
| 4865037 | Chin | Sep 1989 | A |
| 4967746 | Vandegriff | Nov 1990 | A |
| 5036854 | Schollmeyer | Aug 1991 | A |
| 5125904 | Lee | Jun 1992 | A |
| 5129394 | Mehra | Jul 1992 | A |
| 5176135 | Fain | Jan 1993 | A |
| 5203348 | Dahl | Apr 1993 | A |
| 5231996 | Bardy | Aug 1993 | A |
| 5255691 | Otten | Oct 1993 | A |
| 5255692 | Neubauer | Oct 1993 | A |
| 5273053 | Pohndorf | Dec 1993 | A |
| 5300106 | Dahl | Apr 1994 | A |
| 5312355 | Lee | May 1994 | A |
| 5336252 | Cohen | Aug 1994 | A |
| 5364361 | Battenfield | Nov 1994 | A |
| 5391156 | Hildwein | Feb 1995 | A |
| 5403355 | Alt | Apr 1995 | A |
| 5441504 | Pohndorf | Aug 1995 | A |
| 5456699 | Armstrong | Oct 1995 | A |
| 5476493 | Muff | Dec 1995 | A |
| 5509924 | Paspa | Apr 1996 | A |
| 5534018 | Wahlstrand | Jul 1996 | A |
| 5534022 | Hoffmann | Jul 1996 | A |
| 5545205 | Schulte | Aug 1996 | A |
| 5562677 | Hildwein | Oct 1996 | A |
| 5564615 | Bishop | Oct 1996 | A |
| 5571215 | Sterman | Nov 1996 | A |
| 5613953 | Pohndorf | Mar 1997 | A |
| 5626587 | Bishop | May 1997 | A |
| 5645580 | Moaddeb | Jul 1997 | A |
| 5662662 | Bishop | Sep 1997 | A |
| 5690648 | Fogarty | Nov 1997 | A |
| 5716392 | Bourgeois | Feb 1998 | A |
| 5728151 | Garrison | Mar 1998 | A |
| 5752526 | Cosgrove | May 1998 | A |
| 5752970 | Yoon | May 1998 | A |
| 5776110 | Guy | Jul 1998 | A |
| 5779699 | Lipson | Jul 1998 | A |
| 5814076 | Brownlee | Sep 1998 | A |
| 5823946 | Chin | Oct 1998 | A |
| 5830214 | Flom | Nov 1998 | A |
| 5871532 | Schroeppel | Feb 1999 | A |
| 5895414 | Sanchez-Zambrano | Apr 1999 | A |
| 5904711 | Flom | May 1999 | A |
| 5941819 | Chin | Aug 1999 | A |
| 5944732 | Raulerson | Aug 1999 | A |
| 5951518 | Licata | Sep 1999 | A |
| 6024704 | Meador | Feb 2000 | A |
| 6032079 | Kenknight | Feb 2000 | A |
| 6076012 | Swanson | Jun 2000 | A |
| 6099547 | Gellman | Aug 2000 | A |
| 6104957 | Alo | Aug 2000 | A |
| 6122552 | Tockman | Sep 2000 | A |
| 6134478 | Spehr | Oct 2000 | A |
| 6159198 | Gardeski | Dec 2000 | A |
| 6183485 | Thomason | Feb 2001 | B1 |
| 6228052 | Pohndorf | May 2001 | B1 |
| 6251418 | Ahern | Jun 2001 | B1 |
| 6283127 | Sterman | Sep 2001 | B1 |
| 6324414 | Gibbons | Nov 2001 | B1 |
| 6415187 | Kuzma | Jul 2002 | B1 |
| 6445954 | Olive | Sep 2002 | B1 |
| 6478028 | Paolitto | Nov 2002 | B1 |
| 6497651 | Kan | Dec 2002 | B1 |
| 6544247 | Gardeski | Apr 2003 | B1 |
| 6575919 | Reiley | Jun 2003 | B1 |
| 6647292 | Bardy | Nov 2003 | B1 |
| 6650945 | Helland | Nov 2003 | B2 |
| 6651672 | Roth | Nov 2003 | B2 |
| 6706052 | Chin | Mar 2004 | B1 |
| 6718203 | Weiner | Apr 2004 | B2 |
| 6721597 | Bardy | Apr 2004 | B1 |
| 6730083 | Freigang | May 2004 | B2 |
| 6733500 | Kelley | May 2004 | B2 |
| 6749574 | OKeefe | Jun 2004 | B2 |
| 6770070 | Balbierz | Aug 2004 | B1 |
| 6772014 | Coe | Aug 2004 | B2 |
| 6836687 | Kelley | Dec 2004 | B2 |
| 6866044 | Bardy | Mar 2005 | B2 |
| 6868291 | Bonner | Mar 2005 | B1 |
| 6887229 | Kurth | May 2005 | B1 |
| 6889093 | Flammang | May 2005 | B1 |
| 6890295 | Michels | May 2005 | B2 |
| 6918908 | Bonner | Jul 2005 | B2 |
| 6952610 | Ostroff | Oct 2005 | B2 |
| 6999819 | Swoyer | Feb 2006 | B2 |
| 7033326 | Pianca | Apr 2006 | B1 |
| 7039459 | Bardy | May 2006 | B2 |
| 7039465 | Bardy | May 2006 | B2 |
| 7050851 | Plombon | May 2006 | B2 |
| 7065410 | Bardy | Jun 2006 | B2 |
| 7069083 | Finch | Jun 2006 | B2 |
| 7096064 | Deno | Aug 2006 | B2 |
| 7117039 | Manning | Oct 2006 | B2 |
| 7120496 | Bardy | Oct 2006 | B2 |
| 7146212 | Bardy | Dec 2006 | B2 |
| 7149575 | Ostroff | Dec 2006 | B2 |
| 7184830 | Echt | Feb 2007 | B2 |
| 7191015 | Amson | Mar 2007 | B2 |
| 7195637 | Mika | Mar 2007 | B2 |
| 7218970 | Ley | May 2007 | B2 |
| 7229450 | Chitre | Jun 2007 | B1 |
| 7239925 | Bardy | Jul 2007 | B2 |
| 7272448 | Morgan | Sep 2007 | B1 |
| 7288096 | Chin | Oct 2007 | B2 |
| 7316667 | Lindstrom | Jan 2008 | B2 |
| 7319905 | Morgan | Jan 2008 | B1 |
| 7322960 | Yamamoto | Jan 2008 | B2 |
| 7353067 | Helland | Apr 2008 | B1 |
| 7369899 | Malinowski | May 2008 | B2 |
| 7373207 | Lattouf | May 2008 | B2 |
| 7389134 | Karicherla | Jun 2008 | B1 |
| 7398781 | Chin | Jul 2008 | B1 |
| 7450997 | Pianca | Nov 2008 | B1 |
| 7496408 | Ghanem | Feb 2009 | B2 |
| 7499758 | Cates | Mar 2009 | B2 |
| 7515969 | Tockman | Apr 2009 | B2 |
| 7539542 | Malinowski | May 2009 | B1 |
| 7546165 | Zarembo | Jun 2009 | B2 |
| 7627375 | Bardy | Dec 2009 | B2 |
| 7655014 | Ko | Feb 2010 | B2 |
| 7736330 | Bardy | Jun 2010 | B2 |
| 7751885 | Bardy | Jul 2010 | B2 |
| 7761150 | Ghanem | Jul 2010 | B2 |
| 7765014 | Eversull | Jul 2010 | B2 |
| 7801622 | Camps | Sep 2010 | B2 |
| 7837671 | Eversull | Nov 2010 | B2 |
| 7846088 | Ness | Dec 2010 | B2 |
| 7850610 | Ferek-Petric | Dec 2010 | B2 |
| 7853311 | Webb | Dec 2010 | B1 |
| 7890191 | Rutten | Feb 2011 | B2 |
| 7908015 | Lazeroms | Mar 2011 | B2 |
| 7930028 | Lang | Apr 2011 | B2 |
| 7930040 | Kelsch | Apr 2011 | B1 |
| 7967833 | Sterman | Jun 2011 | B2 |
| 7983765 | Doan | Jul 2011 | B1 |
| 8060207 | Wallace | Nov 2011 | B2 |
| 8065020 | Ley | Nov 2011 | B2 |
| 8066702 | Rittman, III | Nov 2011 | B2 |
| 8090451 | Tyson, Jr. | Jan 2012 | B2 |
| 8155755 | Flynn | Apr 2012 | B2 |
| 8157813 | Ko | Apr 2012 | B2 |
| 8260436 | Gerber | Sep 2012 | B2 |
| 8280527 | Eckerdal | Oct 2012 | B2 |
| 8332036 | Hastings | Dec 2012 | B2 |
| 8340779 | Harris | Dec 2012 | B2 |
| 8355786 | Malinowski | Jan 2013 | B2 |
| 8386052 | Harris | Feb 2013 | B2 |
| 8394079 | Drake | Mar 2013 | B2 |
| 8435208 | Bardy | May 2013 | B2 |
| 8442620 | Silipo | May 2013 | B2 |
| 8452421 | Thenuwara | May 2013 | B2 |
| 8454552 | Bardy | Jun 2013 | B2 |
| 8457742 | Jacobson | Jun 2013 | B2 |
| 8478424 | Tronnes | Jul 2013 | B2 |
| 8478426 | Barker | Jul 2013 | B2 |
| 8478431 | Griswold | Jul 2013 | B2 |
| 8483841 | Sanghera | Jul 2013 | B2 |
| 8532789 | Smits | Sep 2013 | B2 |
| 8543222 | Sochor | Sep 2013 | B1 |
| 8594809 | Yang | Nov 2013 | B2 |
| 8731659 | Hansen | May 2014 | B2 |
| 8886311 | Anderson | Nov 2014 | B2 |
| 9079035 | Sanghera | Jul 2015 | B2 |
| 9220913 | Christie | Dec 2015 | B2 |
| 9439653 | Avneri | Sep 2016 | B2 |
| 9468754 | Martinez | Oct 2016 | B2 |
| 9622778 | Wengreen | Apr 2017 | B2 |
| 9636505 | Sanghera | May 2017 | B2 |
| 9636512 | Cinbis | May 2017 | B2 |
| 9707389 | McGeehan | Jul 2017 | B2 |
| 9717898 | Thompson-Nauman | Aug 2017 | B2 |
| 9757190 | Evans | Sep 2017 | B2 |
| 9855414 | Marshall | Jan 2018 | B2 |
| 10022539 | Sanghera | Jul 2018 | B2 |
| 10080905 | Anderson | Sep 2018 | B2 |
| 10130824 | Grinberg | Nov 2018 | B2 |
| 10137295 | Marshall | Nov 2018 | B2 |
| 10471267 | Thompson-Nauman | Nov 2019 | B2 |
| 10532203 | Thompson-Nauman | Jan 2020 | B2 |
| 10556117 | Thompson-Nauman | Feb 2020 | B2 |
| 10661073 | Marshall | May 2020 | B2 |
| 10668270 | Thompson-Nauman | Jun 2020 | B2 |
| 10722704 | Min | Jul 2020 | B2 |
| 10758228 | Zenz-Olson | Sep 2020 | B2 |
| 10842998 | Keefe | Nov 2020 | B2 |
| 10881850 | Baudino | Jan 2021 | B2 |
| 10940325 | Grinberg | Mar 2021 | B2 |
| 11433232 | Thompson-Nauman | Sep 2022 | B2 |
| 20020035381 | Bardy | Mar 2002 | A1 |
| 20020035388 | Lindemans | Mar 2002 | A1 |
| 20020042629 | Bardy | Apr 2002 | A1 |
| 20020072686 | Hoey | Jun 2002 | A1 |
| 20020072773 | Bardy | Jun 2002 | A1 |
| 20020120294 | Kroll | Aug 2002 | A1 |
| 20020133203 | Mouchawar | Sep 2002 | A1 |
| 20020143380 | Dahl | Oct 2002 | A1 |
| 20030045904 | Bardy | Mar 2003 | A1 |
| 20030074041 | Parry | Apr 2003 | A1 |
| 20030088278 | Bardy | May 2003 | A1 |
| 20030088301 | King | May 2003 | A1 |
| 20030097153 | Bardy | May 2003 | A1 |
| 20030114905 | Kuzma | Jun 2003 | A1 |
| 20030114906 | Booker | Jun 2003 | A1 |
| 20030114908 | Flach | Jun 2003 | A1 |
| 20030120264 | Lattouf | Jun 2003 | A1 |
| 20030130581 | Salo | Jul 2003 | A1 |
| 20030187458 | Carlson | Oct 2003 | A1 |
| 20030208153 | Stenzel | Nov 2003 | A1 |
| 20040059348 | Geske | Mar 2004 | A1 |
| 20040064176 | Min | Apr 2004 | A1 |
| 20040088035 | Guenst | May 2004 | A1 |
| 20040102829 | Bonner | May 2004 | A1 |
| 20040143284 | Chin | Jul 2004 | A1 |
| 20040158185 | Moran | Aug 2004 | A1 |
| 20040167416 | Lee | Aug 2004 | A1 |
| 20040210293 | Bardy | Oct 2004 | A1 |
| 20040215240 | Lovett | Oct 2004 | A1 |
| 20040230282 | Cates | Nov 2004 | A1 |
| 20040236396 | Coe | Nov 2004 | A1 |
| 20050027328 | Greenstein | Feb 2005 | A1 |
| 20050049663 | Harris | Mar 2005 | A1 |
| 20050075649 | Bova | Apr 2005 | A1 |
| 20050080470 | Westlund | Apr 2005 | A1 |
| 20050131505 | Yokoyama | Jun 2005 | A1 |
| 20050165324 | Receveur | Jul 2005 | A1 |
| 20050192639 | Bardy | Sep 2005 | A1 |
| 20050288731 | Shames | Dec 2005 | A1 |
| 20050288758 | Jones | Dec 2005 | A1 |
| 20060041295 | Osypka | Feb 2006 | A1 |
| 20060047333 | Tockman | Mar 2006 | A1 |
| 20060085039 | Hastings | Apr 2006 | A1 |
| 20060089699 | Imran | Apr 2006 | A1 |
| 20060116746 | Chin | Jun 2006 | A1 |
| 20060122676 | Ko | Jun 2006 | A1 |
| 20060129202 | Armstrong | Jun 2006 | A1 |
| 20060136004 | Cowan | Jun 2006 | A1 |
| 20060161205 | Mitrani | Jul 2006 | A1 |
| 20060224222 | Bradley | Oct 2006 | A1 |
| 20060241711 | Sathaye | Oct 2006 | A1 |
| 20060247672 | Vidlund | Nov 2006 | A1 |
| 20060247688 | Olson | Nov 2006 | A1 |
| 20060247753 | Wenger | Nov 2006 | A1 |
| 20060253181 | Schulman | Nov 2006 | A1 |
| 20060266368 | Heintz | Nov 2006 | A1 |
| 20070021736 | Johnson | Jan 2007 | A1 |
| 20070023947 | Ludwig | Feb 2007 | A1 |
| 20070066998 | Hansen | Mar 2007 | A1 |
| 20070088394 | Jacobson | Apr 2007 | A1 |
| 20070100409 | Worley | May 2007 | A1 |
| 20070118034 | Mark | May 2007 | A1 |
| 20070150015 | Zhang | Jun 2007 | A1 |
| 20070150023 | Ignagni | Jun 2007 | A1 |
| 20070179388 | Larik | Aug 2007 | A1 |
| 20070197859 | Schaer | Aug 2007 | A1 |
| 20070208402 | Helland | Sep 2007 | A1 |
| 20070249992 | Bardy | Oct 2007 | A1 |
| 20080015590 | Sanders | Jan 2008 | A1 |
| 20080021505 | Hastings | Jan 2008 | A1 |
| 20080027488 | Coles | Jan 2008 | A1 |
| 20080039866 | Stetz | Feb 2008 | A1 |
| 20080046056 | OConnor | Feb 2008 | A1 |
| 20080103575 | Gerber | May 2008 | A1 |
| 20080183230 | Kemmetmueller | Jul 2008 | A1 |
| 20080183254 | Bly | Jul 2008 | A1 |
| 20080242976 | Robertson | Oct 2008 | A1 |
| 20080243196 | Libbus | Oct 2008 | A1 |
| 20080243219 | Malinowski | Oct 2008 | A1 |
| 20080269716 | Bonde | Oct 2008 | A1 |
| 20080294217 | Lian | Nov 2008 | A1 |
| 20080300644 | Sathaye | Dec 2008 | A1 |
| 20090000629 | Hornscheidt | Jan 2009 | A1 |
| 20090054947 | Bourn | Feb 2009 | A1 |
| 20090069803 | Starkebaum | Mar 2009 | A1 |
| 20090157091 | Buysman | Jun 2009 | A1 |
| 20090209854 | Parihar | Aug 2009 | A1 |
| 20090209970 | Tanaka | Aug 2009 | A1 |
| 20090222021 | Chang | Sep 2009 | A1 |
| 20090259283 | Brandt | Oct 2009 | A1 |
| 20090264780 | Schilling | Oct 2009 | A1 |
| 20090270962 | Yang | Oct 2009 | A1 |
| 20090326346 | Kracker | Dec 2009 | A1 |
| 20100016935 | Strandberg | Jan 2010 | A1 |
| 20100030227 | Kast | Feb 2010 | A1 |
| 20100030228 | Havel | Feb 2010 | A1 |
| 20100042110 | Kelley | Feb 2010 | A1 |
| 20100056858 | Mokelke | Mar 2010 | A1 |
| 20100082087 | Silipo | Apr 2010 | A1 |
| 20100094252 | Wengreen | Apr 2010 | A1 |
| 20100113963 | Smits | May 2010 | A1 |
| 20100125194 | Bonner | May 2010 | A1 |
| 20100137879 | Ko | Jun 2010 | A1 |
| 20100137949 | Mazgalev | Jun 2010 | A1 |
| 20100152747 | Padiy | Jun 2010 | A1 |
| 20100152798 | Sanghera | Jun 2010 | A1 |
| 20100152799 | Sanghera | Jun 2010 | A1 |
| 20100185268 | Fowler | Jul 2010 | A1 |
| 20100198041 | Christian | Aug 2010 | A1 |
| 20100211064 | Mahapatra | Aug 2010 | A1 |
| 20100217298 | Bardy | Aug 2010 | A1 |
| 20100217301 | Bardy | Aug 2010 | A1 |
| 20100241189 | Dobak | Sep 2010 | A1 |
| 20100305428 | Bonner | Dec 2010 | A1 |
| 20100318098 | Lund | Dec 2010 | A1 |
| 20100324579 | Bardy | Dec 2010 | A1 |
| 20100331868 | Bardy | Dec 2010 | A1 |
| 20100331938 | Sommer | Dec 2010 | A1 |
| 20110009933 | Barker | Jan 2011 | A1 |
| 20110024491 | Jamali | Feb 2011 | A1 |
| 20110066185 | Wotton, III | Mar 2011 | A1 |
| 20110071540 | Kast | Mar 2011 | A1 |
| 20110077708 | Ostroff | Mar 2011 | A1 |
| 20110093034 | Kast | Apr 2011 | A1 |
| 20110125163 | Rutten | May 2011 | A1 |
| 20110152706 | Christopherson | Jun 2011 | A1 |
| 20110155780 | Boudreaux | Jun 2011 | A1 |
| 20110178566 | Stahmann | Jul 2011 | A1 |
| 20110208261 | Levine | Aug 2011 | A1 |
| 20110210156 | Smith | Sep 2011 | A1 |
| 20110224680 | Barker | Sep 2011 | A1 |
| 20110224681 | McDonald | Sep 2011 | A1 |
| 20110230906 | Modesitt | Sep 2011 | A1 |
| 20110257660 | Jones | Oct 2011 | A1 |
| 20110257717 | Zimmerman | Oct 2011 | A1 |
| 20120016377 | Geroy | Jan 2012 | A1 |
| 20120029335 | Sudam | Feb 2012 | A1 |
| 20120035697 | Stone | Feb 2012 | A1 |
| 20120037291 | Goolishian | Feb 2012 | A1 |
| 20120078266 | Tyson | Mar 2012 | A1 |
| 20120089153 | Christopherson | Apr 2012 | A1 |
| 20120097174 | Spotnitz | Apr 2012 | A1 |
| 20120109250 | Cates | May 2012 | A1 |
| 20120123496 | Schotzko | May 2012 | A1 |
| 20120130465 | Risi | May 2012 | A1 |
| 20120191106 | Ko | Jul 2012 | A1 |
| 20120209283 | Zhu | Aug 2012 | A1 |
| 20120209298 | McClurg | Aug 2012 | A1 |
| 20120245433 | Ahern | Sep 2012 | A1 |
| 20120302863 | O'Neill | Nov 2012 | A1 |
| 20120323253 | Garai | Dec 2012 | A1 |
| 20130006326 | Ackermann | Jan 2013 | A1 |
| 20130041345 | Kilcoin | Feb 2013 | A1 |
| 20130090676 | Journey | Apr 2013 | A1 |
| 20130103049 | Bonde | Apr 2013 | A1 |
| 20130116529 | Min | May 2013 | A1 |
| 20130158564 | Harris | Jun 2013 | A1 |
| 20130178711 | Avneri | Jul 2013 | A1 |
| 20130178871 | Koogle, Jr. | Jul 2013 | A1 |
| 20130226266 | Murtonen | Aug 2013 | A1 |
| 20130237781 | Gyrn | Sep 2013 | A1 |
| 20130238067 | Baudino | Sep 2013 | A1 |
| 20130253531 | Kawaura | Sep 2013 | A1 |
| 20130261597 | Spedden | Oct 2013 | A1 |
| 20130261687 | Xi | Oct 2013 | A1 |
| 20130296880 | Kelley | Nov 2013 | A1 |
| 20130327342 | Watschke | Dec 2013 | A1 |
| 20130338707 | Killion | Dec 2013 | A1 |
| 20140005755 | Wolf, II | Jan 2014 | A1 |
| 20140018872 | Siejko | Jan 2014 | A1 |
| 20140180273 | Nair | Jun 2014 | A1 |
| 20140200602 | Saad | Jul 2014 | A1 |
| 20140243844 | Clancy | Aug 2014 | A1 |
| 20140257421 | Sanghera | Sep 2014 | A1 |
| 20140330208 | Christie | Nov 2014 | A1 |
| 20140330248 | Thompson-Nauman | Nov 2014 | A1 |
| 20140330287 | Thompson-Nauman | Nov 2014 | A1 |
| 20140330325 | Thompson-Nauman | Nov 2014 | A1 |
| 20140330326 | Thompson-Nauman | Nov 2014 | A1 |
| 20140330327 | Thompson-Nauman | Nov 2014 | A1 |
| 20140330328 | Christie | Nov 2014 | A1 |
| 20140330329 | Thompson-Nauman | Nov 2014 | A1 |
| 20140330331 | Thompson-Nauman | Nov 2014 | A1 |
| 20150013689 | Shackelford | Jan 2015 | A1 |
| 20150051612 | Schmidt | Feb 2015 | A1 |
| 20150051615 | Schmidt | Feb 2015 | A1 |
| 20150088155 | Stahmann | Mar 2015 | A1 |
| 20150133954 | Seifert | May 2015 | A1 |
| 20150142069 | Sambelashvili | May 2015 | A1 |
| 20150151114 | Black | Jun 2015 | A1 |
| 20150157497 | Hufford | Jun 2015 | A1 |
| 20150223906 | O'Neill | Aug 2015 | A1 |
| 20150313633 | Gross | Nov 2015 | A1 |
| 20150328473 | Bodner | Nov 2015 | A1 |
| 20160051159 | Mazaeva | Feb 2016 | A1 |
| 20160067478 | McGeehan | Mar 2016 | A1 |
| 20160067479 | Marcovecchio | Mar 2016 | A1 |
| 20160067480 | Sanghera | Mar 2016 | A1 |
| 20160067488 | Sanghera | Mar 2016 | A1 |
| 20160144192 | Sanghera | May 2016 | A1 |
| 20160175007 | Valbuena | Jun 2016 | A1 |
| 20160175581 | Gordon | Jun 2016 | A1 |
| 20160184047 | Weir | Jun 2016 | A1 |
| 20160346059 | McNeely | Dec 2016 | A1 |
| 20170224995 | Sanghera | Aug 2017 | A1 |
| 20170259078 | Howard | Sep 2017 | A1 |
| 20170304019 | Sanghera | Oct 2017 | A1 |
| 20170304634 | Sanghera | Oct 2017 | A1 |
| 20180021572 | McGeehan | Jan 2018 | A1 |
| 20180028804 | Pianca | Feb 2018 | A1 |
| 20180050199 | Sanghera | Feb 2018 | A1 |
| 20180193060 | Reddy | Jul 2018 | A1 |
| 20190105489 | Thompson-Nauman | Apr 2019 | A1 |
| 20200376265 | Sanghera | Dec 2020 | A1 |
| 20200398044 | Sanghera | Dec 2020 | A1 |
| 20210113295 | Sanghera | Apr 2021 | A1 |
| 20210187313 | Grinberg | Jun 2021 | A1 |
| 20210370080 | Sanghera | Dec 2021 | A1 |
| 20210370081 | Sanghera | Dec 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 0668087 | Aug 1995 | EP |
| 1530983 | May 2005 | EP |
| 2346419 | Jul 2011 | EP |
| 2464418 | Jun 2012 | EP |
| 2967644 | Jan 2016 | EP |
| 2994193 | Mar 2016 | EP |
| 2994194 | Mar 2016 | EP |
| 3173043 | May 2017 | EP |
| 3429686 | Jan 2019 | EP |
| 2002026315 | Apr 2002 | WO |
| 2006115772 | Nov 2006 | WO |
| 2009148941 | Dec 2009 | WO |
| 2013163267 | Oct 2013 | WO |
| 2015143327 | Sep 2015 | WO |
| 2017198472 | Nov 2017 | WO |
| 2018009913 | Jan 2018 | WO |
| Entry |
|---|
| Brown, Charles G., et. al. ‘Injuries Associated with Percutaneous Placement of Transthoracic Pacemakers.’ Annals of Emergency Medicine 14.3 (1985): 223-28. |
| Brown, Charles G., et. al. ‘Placement Accuracy of Percutaneous Transthoracic Pacemakers.’ The American Journal of Emergency Medicine 3.3 (1985): 193-98. |
| Corrected Notice of Allowability dated Mar. 3, 2021 for U.S. Appl. No. 16/267,255 (pp. 1-2). |
| Extended European Search Report dated Dec. 17, 2020 for EP App. No. 20198569.4, 8 pages. |
| International Search Report and Written Opinion dated Sep. 21, 2020, International Application No. PCT/US2020/035268; (10 pages). |
| International Search Report and Written Opinion dated Jan. 24, 2022, International application No. PCT/IB2021/056065. |
| Nagdev, Arun, and Daniel Mantuani. ‘A Novel In-plane Technique for Ultrasound-guided Pericardiocentesis.’ Tlie American Journal of Emergency Medicine 31.9 (2013): 1424.e5-1424.e9, 5 pages. |
| Notice of Allowance dated Apr. 13, 2020 for U.S. Appl. No. 15/644,714 (pp. 1-9). |
| Notice of Allowance dated Apr. 23, 2021 for U.S. Appl. No. 16/416,102 (pp. 1-5). |
| Notice of Allowance dated Dec. 23, 2020 for U.S. Appl. No. 16/409,200 (pp. 1-5). |
| Notice of Allowance dated Feb. 9, 2021 for U.S. Appl. No. 16/267,255 (pp. 1-5). |
| Notice of Allowance dated May 27, 2021 for U.S. Appl. No. 14/846,578 (pp. 1-7). |
| Office Action (Final Rejection) dated Mar. 16, 2022 for U.S. Appl. No. 16/573,889 (pp. 1-18). |
| Office Action (Final Rejection) dated Aug. 5, 2022 for U.S. Appl. No. 16/888,468 (pp. 1-18). |
| Office Action (Non-Final Rejection) dated Mar. 15, 2022 for U.S. Appl. No. 16/888,468 (pp. 1-15). |
| Office Action (Non-Final Rejection) dated May 13, 2022 for U.S. Appl. No. 16/888,462 (pp. 1-8). |
| Office Action (Non-Final Rejection) dated Jul. 7, 2022 for U.S. Appl. No. 16/573,889 (pp. 1-12). |
| Office Action (Non-Final Rejection) dated Sep. 13, 2021 for U.S. Appl. No. 16/573,889 (pp. 1-17). |
| Office Action (Notice of Allowance and Fees Due (PTOL-85)) dated Sep. 14, 2021 for U.S. Appl. No. 16/453,932 (pp. 1-8). |
| Office Action dated Feb. 28, 2020 for U.S. Appl. No. 14/846,578 (pp. 1-8). |
| Office Action dated Jan. 11, 2021 for U.S. Appl. No. 16/416,102 (pp. 1-6). |
| Office Action dated May 14, 2020 for U.S. Appl. No. 16/267,255 (pp. 1-8). |
| Office Action dated May 25, 2021 for U.S. Appl. No. 16/453,932 (pp. 1-11). |
| Office Action dated Nov. 10, 2020 for U.S. Appl. No. 16/409,200 (pp. 1-6). |
| Office Action dated Nov. 2, 2020 for U.S. Appl. No. 16/267,255 (pp. 1-12). |
| Pai, N. V., et al. ‘Relation of Internal Thoracic Artery to Lateral Sternal Border and Its Significance in Clinical Procedures.’ International Journal of Biological & Medical Research 4.4 (2013): 3633-636. |
| PCT/US2017/041265; International Search Report and Written Opinion dated Sep. 25, 2017; 11 pages. |
| International Preliminary Report on Patentability dated Jan. 19, 2023, International application No. PCT/IB2021/056065. |
| CA Search Report dated Aug. 5, 2022; 3 pages. |
| CA Search Report dated Aug. 4, 2022; 4 pages. |
| EP App. No. 15837876.0; Communication pursuant to Rule 71(3) dated Sep. 20, 2022; 86 pages. |
| CA Search Report dated Mar. 9, 2023; 5 pages. |
| CA Search Report dated Mar. 15, 2023; 3 pages. |
| CA Notice of Allowance dated Apr. 26, 2023; 1 page. |
| EP App. No. 15838014.7; Communication pursuant to Article 94(3) dated May 2, 2023; 4 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20220226070 A1 | Jul 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62360110 | Jul 2016 | US | |
| 62146569 | Apr 2015 | US | |
| 62083516 | Nov 2014 | US | |
| 62045683 | Sep 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 17581543 | Jan 2022 | US |
| Child | 17715814 | US | |
| Parent | 16453932 | Jun 2019 | US |
| Child | 17581543 | US | |
| Parent | 15644714 | Jul 2017 | US |
| Child | 16453932 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14846578 | Sep 2015 | US |
| Child | 15644714 | US |
